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1 ABREVIATION 
 
5HT2AR  5-hydroxy-tryptamine-2A serotonin receptor  
BKPyV  BK polyomavirus  
BKPyVAN BKPyV-associated nephropathy 
BKPyVHC BKPyV-associated hemorrhagic cystitis 
BP  Base pairs  
BRE  B recognition element 
CMV   Cytomegalovirus  
CNS  Central nervous system 
CPE  Core promoter element   
CSF   Cerebrospinal fluid  
DNA   Deoxyribonucleic acid 
DPE  Downstream promoter element 
Ds-DNA Double-stranded deoxyribonucleic acid 
ER   Endoplasmic reticulum 
ERAD  Endoplasmic reticulum-associated degredation  
EVGR  Early viral gene region  
HIV-1   Human immunodeficiency virus-1  
HPyV10  Human polyomavirus 10  
HPyV12  Human polyomavirus 12  
HPyV6 Human polyomavirus 6   
HPyV7 Human polyomavirus 7   
HPyV9 Human polyomavirus 9  
HPyVs  Human polyomaviruses 
Inr  Initiation element  
JCPyV  JC polyomavirus  
LTag   Large tumor antigen 
LVGR  Late viral gene region  
MCPyV  Merkel cell polyomavirus 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mRNA  Messenger ribonucleic acid  
miRNA Micro RNA 
NCCR  Non-coding control region  
NK   Cells natural killer cells  
NLS  Nuclear localization signal  
PBMCs  Peripheral blood mononuclear cells  
PML   Progressive multifocal leukoencephalopathy  
pRB   Retinoblastoma protein  
PyVAN  Polyomavirus associated nephropathy  
PyVHC  Polyomavirus associated hemorrhagic cystitis  
PyVs   polyomaviruses  
RNA   Ribonucleic acid 
RCA  Rolling circle amplification  
RPA   Replication protein A  
rr-NCCR  Rearranged non-coding control region  
sTag   Small T antigen  
STLPyV  Saint Louis polyomavirus  
SV40   Simian virus 40  
TSS  Transcription start site 
TSPyV  Trichodysplasia spinulosa polyomavirus  
VLP(s)  Virus-like particle(s)  
Vp1  Major capsid protein 1   
Vp2  Minor capsid protein 2   
Vp3  Minor capsid protein 3  
ww  Wild type or Archetype  
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2 ABSTRACT 
With the advent of advanced molecular biology techniques, 13 human 
polyomaviruses (HPyVs) have been identified from different human body 
compartments. Generally, infection with HPyVs is harmless in immunocompetent 
people. However, some of these viruses are known to cause severe morbidities in 
the immunosuppressed. Five HPyVs, BK polyomavirus (BKPyV), JC polyomavirus 
(JCPyV), Merkel cell polyomavirus (MCPyV), Trichodysplasia spinolosa polyomavirus 
(TSPyV) and HPyV7 are known to cause diseases. Although other HPyVs have been 
detected in diseased tissues or cancers, evidence of their involvement is lacking. 
Furthermore, less is known about the cell tropism, replication in cell culture, and gene 
regulation of HPyVs. The non-coding control region (NCCR) of HPyVs functions as a 
bi-directional promoter/enhancer system, coordinating the respective steps of the 
viral replication cycle. Furthermore, it also determines viral persistence, host cell 
specificity, replication and virulence. Efficient replication of BKPyV and JCPyV have 
been demonstrated in cell cultures, but less is known with regards to the novel 
HPyVs. NCCR activity which can be used as an indicator of HPyV cell tropism and 
replication in cell culture is lacking for the newly discovered HPyVs. Despite 
similarities in the genome organization of HPyVs, the NCCRs of the HPyVs are 
different with respect to large T antigen binding sites, transcriptional factor binding 
sites (TFBS) and length. We hypothesized that the HPyV-NCCRs will display 
different activity in the same or different host cells. A bi-directional reporter vector 
recapitulating the HPyV genome with a red fluorescence protein (dsRed2) and a 
green fluorescence protein (EGFP) as markers of EVGR and LVGR, respectively, 
was designed. The reporter was used to analyze the NCCR activity of the 13 HPyVs 
in different cell lines originating from kidney, skin, lungs, cervix, brain and colon 
cancers. Our result demonstrated that the bi-directional HPyV-NCCR activity 
substantially differ in the same and different host cells. Indicating that the HPyV-
NCCRs differentially sense and interpret the host cells’ transcription factors and 
different host cells’ transcription factors modulate the basal HPyV-NCCRs expression. 
As previously reported for BKPyV and JCPyV, rearranged (rr)-NCCR variants of 
newly discovered HPyVs associated with diseases showed higher EVGR expression 
compared to their respective archetype, indicating the NCCR a major pathogenicity 
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determinant. Analyzing the HPyV-NCCRs’ activity in cell lines expressing T antigens 
(Tags) displayed activation of EVGR expression, suggesting that the bi-directional 
reporter recapitulates an essential NCCR response reported for the viral replication 
cycle. Furthermore, it indicates that cell lines expressing Tags of respective HPyVs 
can be used for the propagation of respective HPyVs. This data serves as a basis for 
understanding host and viral factors that may permit the identification of suitable cell 
culture systems and secondary host cell tropism for HPyVs. However, actual viral 
replication studies are needed to confirm replication of HPyV genomes in some of the 
cell lines tested. Furthermore, the role of the LTag-binding motif with regards to the 
regulation of EVGR and LVGR has been well-characterized in the monkey 
polyomavirus, simian virus 40, although very little is known with respect to the role of 
the LTag-binding motif for HPyVs. Given that the LTag recognition sites influence 
EVGR and LVGR expression and the LTag-binding sites organization of SV40 is 
similar to that of some HPyVs, such as BKPyV, we hypothesized that the role of the 
LTag-binding motif in the regulation of EVGR and LVGR expression in BKPyV is 
potentially similar to that of SV40. The EVGR and LVGR expression of BKPyV 
archetype (ww)-NCCR was compared with those of BKPyV ww-NCCR defective in 
one or more LTag-binding motifs in HEK293, HEK293T and HEK293TT cell lines, 
expressing none, small and large amounts of SV40 LTag, respectively. Our results 
indicated that abundant LTag decreased EVGR-expression by probably interacting 
with LTag binding site A, suggesting abundant LTag expression may down regulate 
EVGR expression, similar to SV40’s-EVGR autoregulation. Contrarily, the LVGR 
expression is proportionally increased in the presence of increasing amounts of LTag 
expression (HEK293T and HEK293TT cells), by LTag potentially interacting with 
binding sites A and D. These results may open avenues for designing new 
therapeutic strategies targeting this reduction of EVGR expression in the presence of 
abundant LTag expression. Actual viral replication studies are needed to verify 
whether these mutants are replicative competent or not.  
Concluding, a basic approach was used to elucidate factors that may allow the 
replication of HPyVs in cell cultures, that will greatly enhance our understanding of 
the basic biology of these viruses. Furthermore, putative host cell tropism of HPyVs 
was suggested. The effect of LTag-binding sites with respect to BKPyV’s EVGR and 
LVGR expression, which could be extrapolated to other HPyVs was shown. 
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3 INTRODUCTION 
3.1 Polyomaviridae 
Polyomaviruses (PyVs) belonging to the family Polyomaviridae infect a wide range of 
vertebrates from birds to mammals. However, PyVs are limited in the species they 
can productively infect (1). The Polyomaviridae Study Group of the International 
Committee on Taxonomy of Viruses has recently revised the family Polyomaviridae 
by a sequence- and host-based rationale (1). Based on the observed distance 
between large T antigen (LTag) coding sequences, at least 73 species of the family 
Polyomaviridae were classified into four genera (Alpha-, Beta-, Gamma- and Delta-
polyomavirus) (2). The Alphapolyomavirus and Betapolyomavirus genera contain 
polyomaviruses that infect a variety of mammals. The gammapolyomavirus genus 
contains avian polyomaviruses, while the genus Deltapolyomavirus contains only four 
human polyomaviruses (HPyVs). The observed distance between LTag-coding 
sequence of HPyVs is shown (Fig. 1). However, the closest neighbor of a HPyV may 
be from a PyV from animals. At least 73 PyVs have been identified so far, of which 
13 are HPyVs detected in different human-body compartments (Fig. 2) (2). 
Specifically BK polyomavirus (BKPyV) (3), JC polyomavirus (JCPyV) (4), Karolinska 
institute polyomavirus (KIPyV) (5), Washington university polyomavirus (WUPyV) (6), 
Merkel cell polyomavirus (MCPyV) (7), human polyomavirus 6 (HPyV6) (8), human 
polyomavirus 7 (HPyV7) (8), Trichodysplasia spinulosa polyomavirus (TSPyV) (9), 
human polyomavirus 9 (HPyV9) (10), human polyomavirus 10 (HPyV10) (11), St. 
Louis polyomavirus (STLPyV) (12) human polyomavirus 12 (HPyV12) (13), New 
Jersey polyomavirus (NJPyV) (14). While this work was in progress, the International 
Agency for Research on Cancer (IARC) in Lyon described a new PyV (LIPyV), which 
now needs confirmation as a HPyV (15). HPyVs generally cause asymptomatic 
infections in early childhood, which can then reactivate upon immunosuppression 
causing severe diseases. Of all these HPyVs, only BKPyV, JCPyV, MCPyV, TSPyV 
and HPyV7 are known to cause diseases (Fig. 2). The seroprevalence of HPyVs is 
up to 99% in the general adult population (Table 1) (16-18), suggesting a low-level 
infection of these viruses in the general population.  
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Fig. 1: A neighbor joining phylogenetic tree without distance corrections based on 
observed distance between HPyVs large T antigen coding sequences. The 
phylogram was constructed after multiple sequence alignment of the large T antigen 
sequences of the HPyVs using clustal omega. Next to each branch the evolutionary 
distance is depicted. Based on the tree, HPyVs could be grouped under 3 genera 
(Alpha-, Beta- and Delta-polyomavirus). GenBank accession numbers, from which 
the large T antigen sequences are based are found in table 6. 
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Fig. 2: The 13 HPyVs identified from different compartment of the human body 
including LIPyV which was discovered recently but needs confirmation as a HPyV 
(indicated with the arrows). The year of identification of each HPyV is depicted. Only 
5 HPyVs highlighted in yellow can cause diseases. BKPyV and JCPyV are the two 
HPyVs that can be efficiently propagated in cell culture. 
3.1.1 Structure and genome architecture of polyomavirus 
Polyomaviruses are non-enveloped viruses with a supercoiled double-stranded 
circular DNA genome of about 5000 base pairs (bp). The genome is associated with 
cellular histones to form a minichromosome. It is encapsidated in an icosahedral-
shaped viral capsid of approximately 45 nano meter (nm) in diameter (19, 20). The 
capsid is made up of 72 pentamers of the major capsid protein, viral protein 1 (Vp1), 
which is capable of self-assembly into viral-like particles (VLPs) (19, 21). Each Vp1 
pentamer is associated with a minor capsid protein, Vp2 or Vp3 (Fig. 3A). The 
genome of polyomaviruses is divided into 3 main regions, the non-coding control 
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region (NCCR) and two transcriptional regions; early viral gene region (EVGR) and 
the late viral gene region (LVGR) (Fig. 3B). They are termed EVGR and LVGR due 
to the time of transcription during the course of the viral replication cycle. The EVGR 
and LVGR are transcribed in opposite strands and directions by the host cell RNA 
polymerase II as a single pre-messenger RNA. 
3.1.1.1 Non-coding control region  
The NCCR functions as a bi-directional promoter, harboring the origin of viral 
replication (ori), early and late promoters, enhancers regions, transcriptional start 
sites and a multitude of transcription factor-binding sites (TFBS). The NCCR can be 
referred to as the ‘’brain’’ of polyomaviruses. It is defined as the region between the 
start codon of the LVGR and the start codon of the EVGR. In  BKPyV and JCPyV, 
the NCCR region proximal to the LVGR contains enhancer elements, LVGR 
transcriptional initiation sites and usually undergoes rearrangements including 
deletions, duplications and point mutations (22), whereas the region proximal to the 
EVGR harbors the origin of viral genome replication, EVGR transcriptional initiation 
sites and mostly not rearranged (23). This region also contains palindromes and 
dyad symmetry elements (23). Rearrangements of NCCR region proximal to the 
LVGR region result in different strains of the same species, which confers tissues 
specific expression of EVGR and LVGR expression. Rearranged BKPyV and JCPyV 
NCCR variants are common in BKPyV- and JCPyV-associated diseases (24-26). 
Nonetheless, BKPyV-induced hemorrhagic cystitis and nephropathy was not linked to 
any particular NCCR architecture (27). Furthermore, polyomaviruses containing 
similar NCCR rearrangement have been reported in different patient groups and 
healthy individuals (18, 28). The exact role of rearranged NCCR variants in 
pathogenesis and the mechanisms of generating the rearrangements are poorly 
understood. Rearranged BKPyV and JCPyV NCCR variants with diverse duplications 
and deletions from patients, have been reported to increase EVGR expression, 
replication capacity and cytopathology in vitro (25, 26). This suggests that BKPyV 
and JCPyV variants with rearranged NCCR can be linked to increase EVGR 
expression, replication capacity and disease (22, 25), which has not been studied for 
the novel HPyVs. A multitude of TFBS within the HPyV NCCR control the cell specific 
EVGR and LVGR expression of HPyVs. The roles of some of these TFBS in the 
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control of BKPyV and JCPyV gene expression are known (29-34), whereas little or 
no information is known with respect to the newly discovered HPyVs. Nonetheless, 
since some of the TFBS are conserved among HPyVs, the knowledge gained from 
BKPyV and JCPyV can be extrapolated to the other HPyVs.  
3.1.1.2 Early viral gene region  
The EVGR pre-mRNA is spliced into different variants encoding for large T antigen 
(LTag), small T antigen (sTag) (Fig. 4) and other T antigens variants, which are 
produced by alternative splicing. Some of the HPyVs encode additional early proteins. 
BKPyV encodes 17kT, JCPyV; T’135, T’136 and T’165, MCPyV; 57KT and ALTO, 
TSPyV; tinyT, 21kT, MTag and ALTO HPyV9; 145T, STLPyV may encode 229T, 
HPyV12; 84T and NJPyV may encode 299T (18). 
3.1.1.3 Late viral gene region  
The LVGR encodes the viral structural proteins, Vp1, Vp2, Vp3 and a non-structural 
late protein, agno, which are produced by alternative translational start sites. Only 
simian virus 40 (SV40), BKPyV and JCPyV encode the late non-structural protein, 
agno. The capsid of PyVs are composed of 72 pentamers of the major capsid protein 
Vp1, which are strengthened by disulphide and calcium bridges, and conserved 
throughout the polyomavirus family (20). These Vp1 pentamers form barrel-like 
structures, and within the hollows of Vp1, are contained minor capsid proteins, Vp2 
and Vp3.  
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Fig. 3: (A) Schematic representation of the HPyV viral particle. (B) Representation of 
general features of the HPyV genome.  
3.1.2 Polyomavirus life cycle 
3.1.2.1 Host cell receptors, viral entry and un-coating  
The detailed mechanisms of polyomavirus entry, trafficking through the cytoplasm 
and nuclear entry is not well understood. However, much of the understanding of the 
polyomavirus life cycle (Fig. 5) have been deduced from investigating SV40, BKPyV 
and JCPyV infection mechanisms (35). Vp1 is known to interact with the host cell 
receptors, as for instance mutation of the Vp1 calcium binding residues block viral 
entry into the host cell, resulting to disruption of virion assembly (36). The monkey 
polyomavirus, SV40 binds the monosialotetrahexosylganglioside (GM1) receptor and 
enters the cell via caveolar-mediated endocytosis. Additionally, SV40 can also 
independently enter the cell via caveolin or clathrin mediated endocytosis (37). On 
the other hand, BKPyV uses the disialoganglioside GT1b and trisialogangliosides 
GD1 as receptors to enter the cells by caveolar-mediated endocytosis, while JCPyV 
binds to serotonin 5-hydroxytryptamine 2A (5-HT2A)  and enters the cell via clathrin-
mediated endocytosis (38, 39). After internalization, the viral particle is trafficked 
through the microtubule network to the endoplasmic reticulum (ER) (40-42). ER 
transiting is unique to PyVs, no other DNA virus known to replicate in the nucleus 
uses this route. Interactions between the PyVs capsid proteins and the ER proteins 
have been well studied in SV40 (43). Partial un-coating of the viral particle takes 
place in the ER. The disulfide-isomerase unlinks the disulfide bonds between the Vp1 
pentamers in the capsid (40, 44). The minor capsid proteins Vp2 and Vp3 become 
accessible with the help of chaperone proteins, which is important for subsequent 
steps in the viral life cycle. Once the viral particle is partially disassembled, it is then 
retrograde-transported from the ER to the cytoplasm via the ER associated 
degradation (ERAD) pathway. The viral particle is then guided into the nucleus via 
the nuclear pore with the help of the nuclear localization signal (NLS) present in Vp2 
and Vp3 (45). 
3.1.2.2 Early viral gene expression 
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The early and late promoters within the NCCR control the bidirectional EVGR and 
LVGR transcription. The EVGR and LVGR transcription progresses outward from the 
NCCR via opposite strands of the genome. Once the virus gets into the nucleus, 
EVGR transcription is initiated by cellular RNA polymerase II and controlled by cis-
acting sequences within the NCCR, such as TATA box, GC-rich sequences and 
enhancers. A single pre-EVGR mRNA is produced which undergoes alternative 
splicing into sTag, LTag and other T antigens spliced variants. The T antigens’ 
coding regions are overlapping at the N-terminal sequence, but differ at the C-
terminal sequence (46).  
3.1.2.2.1 Large T antigen: the multifunctional protein 
The LTag of HPyVs is a multifunctional protein that interacts with numerous cellular 
and viral factors to initiate viral gene expression and viral genome replication (1). The 
structure and functions of the LTag have been largely described in the SV40 model, 
which is also relevant for BKPyV and JCPyV with amino acids homology of 
approximately 81% between SV40 and BKPyV, and 79% between SV40 and JCPyV 
(47). The large T antigen contained five regions that are conserved among HPyVs, 
that is, DnaJ region, LXCXE motif, nuclear localization signal, origin-binding domain 
(OBD) and ATPase/helicase domain. LTag binds to pentanucleotide sequences, 
GRGGC or its compliment GCCYC at the ori via the OBD region (48). The NCCR of 
all HPyVs contains at least one of these pentanucleotide sequences (49). Large T 
antigen binds to the ori within the NCCRs, unwinds the duplex DNA viral genome by 
using the ATPase/helicase activity (48). The ATPase gives the energy required for 
the helicase activity, while a zinc-binding domain proximal to the helicase domain is 
needed for the formation of LTag hexamer at the ori (48). In addition, LTag drives the 
cell into S-phase of the cell cycle resulting in the activation of DNA damage response 
(DDR) in order to promote replication of viral genome. The DnaJ domain cooperates 
with a proximally located motif called LXCXE to bind the retinoblastoma tumor 
suppressor proteins, pRB/p130/p107 (48). This binding disrupts the interactions 
between E2F (E2 transcription factor) and pRB/p130/p107. Dissociating pRB from 
E2F permits the formation of E2F-E2F dimers, which interacts with its target 
sequence and drives S-phase progression and DNA synthesis (48). Normally, 
improper entry of the host cell into S-phase would signal a p53-mediated apoptosis. 
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However, to circumvent the p53-mediated apoptosis, LTag binds p53 via the P53-
binding domain within the helicase domain of LTag and allows progressive viral 
replication (1, 50). This p53 protein is a critical tumor suppressor in humans and its 
involvement in tumorigenesis has been widely demonstrated in the SV40 model (48, 
51).  
Likewise, sTag also has tumorigenic potentials. It promotes cells growth and viral 
replication by interacting with protein phosphatase 2A (PP2A), and disrupts its 
phosphatase ability (52). It has been reported to stimulate intercellular kinases to 
also promote cellular growth pathways (53).  
 
 
Fig. 4: Schematic representation of the large and small T antigens.  
3.1.2.2.2 Viral encoded microRNA 
 
During the viral life cycle, small noncoding RNAs (miRNAs) post-translationally 
regulate gene expression by directed-mRNAs cleavage or repression of translation. 
SV40, BKPyV, JCPyV, and MCPyV encode miRNA that target and deplete early viral 
transcripts, such as LTag mRNA (54-56). SV40 miRNA mutant infected cells were 
observed to be more sensitive to T antigen specific cytotoxic T-cell lysis in vitro, 
suggesting the importance of miRNA in viral evasion of the host immune response. 
However, similar amounts of infectious virions were produced with the SV40 miRNA 
mutant compared to the wild-type (55). Moreover, the stress-induced ligand, UL16 
binding protein 3 (ULBP3), which is important in the activation of the natural killer T-
cell receptor (NKG2D), has been reported to be targeted by BKPyV and JCPyV 
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miRNA (57). The NKG2D mediated killing of infected cells was reduced due to the 
downregulation of ULBP3 by the viral miRNA. This indicated that PyVs could use this 
mechanism to latently infect the host without being eliminated by the host immune 
system (57).  Interestingly, archetype (ww) BKPyV encoded miRNA has been 
reported to be involved in limiting BKPyV ww replication in renal tubular epithelia 
cells (58). Nevertheless, regulation of the miRNA could be accomplished through the 
balance of regulatory elements within the NCCRs controlling EVGR and miRNA 
expression prior to genome replication (58). The BKPyV and JCPyV miRNA is 
encoded on the late strand with complementarity to the 3′ coding end of the T antigen 
mRNA  (Fig. 2B) (54). Since the miRNA is located on the late strand, one could 
suggest that the miRNA is expressed from the late promoter, although it may also be 
expressed from within or outside the NCCR. The miRNA of BKPyV and JCPyV are 
identical; this indicates that in the case of co-infection, the miRNA from each virus 
can downregulates each other’s T antigens expression. Since PyVs use miRNA to 
evade the host immune system, therapeutically targeting miRNA could be used for 
treating PyVs-associated diseases. Therefore, investigating the presence and 
function of miRNA of the other HPyVs is warranted. 
3.1.2.3 Viral genome replication 
PyVs depend on the host cell machineries to replicate its genome. LTag coordinates 
viral genome replication by recruiting multiple host factors required for viral genome 
replication. LTag monomers bind to the viral ori and assemble into two hexamers. 
Once the binding to ori occurs, LTag uses its helicase activity to unwind the double 
stranded DNA (48) (as explained above). Next, replication protein A (RPA) is 
recruited to bind the single stranded unwound DNA, to prevent it from annealing and 
forming secondary structures. 
3.1.2.4 Late viral gene expression 
Concomitantly to viral genome replication, late viral proteins are expressed. LTag 
begins suppression of EVGR expression at this point, but the exact mechanism is not 
well understood. It is suggested that, high LTag amounts binding the ori, particularly 
to LTag binding site I in SV40 (59), results in the downregulation (auto-regulation)  of 
EVGR expression and promotion of LVGR expression. Additionally, miRNA could 
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also be involved as explained above.  LVGR transcription produces at least 3 
structural proteins, Vp1, Vp2 and Vp3. They are encoded in an overlapping manner; 
Vp3 is completely encoded in the 3’ end of Vp2. SV40 has been reported to encode 
Vp4 (60). Furthermore, unlike the other HPyVs the LVGR of SV40, BKPyV and 
JCPyV encodes a small late non-structural protein called agno (6, 7, 61, 62).  
3.1.2.5 Encapsidation and viral release 
In baculovirus expression systems, Vp1 can self-assemble into the capsid protein 
without the presence of Vp2 and Vp3, but Vp1 cannot assemble into the capsid 
protein in the cytoplasm, which might be due to low calcium concentrations in the 
cytoplasm. This theory was supported by the higher calcium concentration in the 
nucleus, where virions were observed by confocal and electron microscopy (19, 21, 
63). The LVGR capsid proteins made in the cytoplasm are transported to the nucleus 
with the help of the nuclear localization signal sequence within the proteins (NLS). 
Once in the nucleus they are assembled into virions. Vp1, the major capsid protein 
associates with minor capsid proteins Vp2 or Vp3 (not encoded by MCPyV), which 
extend internally anchoring the minichromosome. Viral release of the fully assembled 
infectious particles is poorly understood, but thought to occur via a number of 
processes including host cell lysis, agnoprotein increasing membrane permeability, 
Vp3 lytic properties, SV40 Vp4-mediated viroporin release (60, 64, 65). Vp4 was 
reported to be encoded by SV40 and function as a viroporin to form pores for viral 
release (60). However, recently, Henriksen et al. demonstrated that Vp4 is not 
important for viral release, since there wasn’t any difference between wild-type and 
Vp4  mutant release (66).  
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Fig. 5: Schematic representation of polyomavirus life cycle. 1. Attachment of host-
cell receptors. 2. Entry by endocytosis. 3. Transport of viral particle via endosomes to 
ER and later to the nucleus via the nuclear pore. 4 and 5. EVGR transcription and 
translation. 6. Nuclear translocation of LTag and viral genome replication. 7. LVGR 
transcription and translation. 8. Newly-synthesized viral genomes encapsidation. 9. 
Infectious viral particles release. 
3.1.3 The emerging family of polyomaviruses 
3.1.3.1 Murine polyomavirus  
The mouse polyomavirus (MPyV) was one of the first PyV to be isolated by Ludwig 
Gross in 1953 while studying murine leukaemia virus (67). Heat inactivation of an 
inoculum, which usually protects against infection with Murine leukaemia virus, still 
resulted in leukaemia and tumors in the parotids glands of newborn mice. Thus, he 
concluded that the tumor was due to another infectious agent. Gross named this 
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infectious agent after further experimentation “polyoma” due to its ability to cause 
multiple tumors in various tissues in newborn mice. Since the MPyV discovery, viral 
oncogenesis has been intensively studied (46). 
3.1.3.2 Simian Virus 40 
SV40 was discovered in 1960 as a contaminant of a batch of polio vaccines 
generated in primary kidney cells from Rhesus monkeys (68). Between 1955 and 
1963 approximately 100 million adults and children received the polio vaccine and 
the same methods for generating the vaccine were used throughout the world. A 
vacoulating agent, later named Simian virus (SV40) was identified during safety 
testing in some cultures causing cytopathic effect (1, 68). Furthermore, investigations 
of culture systems infected with SV40 revealed that this virus had the ability to cause 
tumors in animal models (69). SV40 has been linked to non-Hodgkin lymphoma, 
adult and pediatric brain tumors, mesothelioma, and osteosarcoma  (70). 
Epidemiological studies show that populations exposed to the SV40-contaminated 
polio vaccine failed to show increased risk of tumor development (71-73). However, 
the understanding of cell cycle and oncogenic pathways that permit the discovery of 
tumor suppressors pRB and p53 was greatly improved due to SV40 research (1, 46, 
74). For more than 50 years the question of whether SV40 infection is an agent of 
human cancer has remained highly controversial (75). 
3.1.3.3 Human Polyomaviruses 
3.1.3.3.1 BK and JC polyomavirus 
BKPyV and JCPyV were the two HPyVs discovered in 1971. They were named after 
the initials of the two patients from whom the viruses were isolated (3, 4, 76). BKPyV 
was isolated from the urine of a kidney transplant recipient (3), while JCPyV was 
isolated from the brain tissue of a progressive multifocal leukoencephalopathy (PML) 
patient (3, 4, 76). Inoculating human fetal brain tissue with isolated JCPyV agent 
revealed that JCPyV was the causative agent of PML, a fatal demyelinating disease 
in the central nervous system (CNS) (4). Infection of BKPyV and JCPyV occurs 
during early childhood. Seroprevalence of BKPyV and JCPyV in the general adult 
population ranges from 50-98% (77). The mechanism of transmission of BKPyV and 
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JCPyV is poorly understood, but thought to be via the respiratory or fecal-oral route 
(78-80). After primary infection of BKPyV or JCPyV, the viruses establish a persistent 
infection, possibly in kidney, neuronal, hematopoietic or lymphoid tissues (81-83). 
BKPyV has been detected in various organs/compartments of the human body; 
peripheral blood mononuclear cells (PBMCs), brain cells, urogenital cells, 
lymphocytes, cervix, rectum, sperm, skin and numerous cancers such as, 
neuroblastoma, osteosarcoma, prostate, cervix and Kaposi’s sarcoma (84-87). 
JCPyV has been detected in PBMCs, kidney, lungs, bone marrow, gastrointestinal 
tract, tonsils, and lymphoid organs and in various cancers such as, B-cell lymphoma, 
lung, colon, urothelial, prostate, esophageal and cancers of the CNS (88-91). 
Reactivation of JCPyV and BKPyV can occur upon immune suppression. The 
incidence of PML has increased greatly with the pandemic of acquired 
immunodeficiency syndrome (AIDS) in the 1980s (90). BKPyV reactivation occurs 
mostly in renal transplant recipients resulting in nephropathy, which is associated 
with the risk of organ rejection (90, 92-94). Reactivation of BKPyV in bone marrow 
transplant (BMT) recipients could lead to hemorrhagic cystitis (95, 96). Both viruses 
are known to have four main serological subtypes, however, the clinical importance 
of these subtypes is poorly understood (97) 
3.1.3.3.2 KI and WU polyomavirus 
Approximately 36 years after the discovery of the first two HPyVs, the interest in 
human polyomaviruses was rekindled in 2007, when two new HPyVs, KIPyV and 
WUPyV, were discovered (6, 62). Similar to the initial detection of BKPyV and 
JCPyV, KIPyV and WUPyV were reported within one month of each other. Using 
large-scale molecular virus screening, KIPyV was detected in a respiratory secretion 
at the Karolinska institute (KI) by Allander et al. Within a month, Gaynor et al., 
identified WUPyV in a respiratory secretion from a child with clinical signs of 
pneumonia at the Washington University (WU) by using high throughput molecular 
sequencing techniques (6, 62). Furthermore, these viruses were also detected in 
respiratory secretions of children with acute respiratory illness (98). Since then, they 
have also been detected in blood, faces, urine, lung, tonsils, cerebrospinal fluid, 
spleen, lymphoid tissue, brain of HIV-infected patients with and without PML (99-102). 
Both viruses are phylogenetically related to each other and belong with BKPyV and 
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JCPyV to the Genus Betapolyomavirus (2, 6). The detection rates of both viruses in 
respiratory secretions by polymerase chain reaction (PCR) were between 0.4%-9% 
in studies conducted throughout the world (5, 6, 62, 98, 103-116). Detection rates in 
immunocompromised populations are estimated to be higher, and many of the 
reports lack appropriate control population and used small cohorts. The detection of 
KIPyV and WUPyV with other respiratory pathogens is common, thus making it 
difficult to draw the etiological link between these two viruses with respiratory 
illnesses (6, 62, 116, 117). The seroprevalence of KIPyV and WUPyV in healthy 
adults’ ranges between 55%-93.3% and 54%-90%, respectively. This suggests a 
wide spread of KIPyV and WUPyV infection (77, 118, 119). Like BKPyV and JCPyV, 
it is hypothesized that KIPyV and WUPyV may persist in their host, reactivate and 
cause disease in immunosuppressed individuals. So far, no study has shown a 
significant difference between KIPyV and WUPyV detection rates in 
immunocompetent or immunocompromised individuals, although higher viral loads of 
KIPyV have been reported in the immunocompromised host (101, 120-127). 
Currently, no possible link of KIPyV and WUPyV to cancer has been made. Moreover, 
a role for both viruses in different cancer types is possible (128-130). Lastly, there 
have been no definitive association of these viruses with any disease. 
3.1.3.3.3 Merkel cell polyomavirus 
One year later (2008), Merkel cell polyomavirus (MCPyV) was detected using a 
digital transcriptome subtraction technique of RNA extracted from a Merkel cell 
carcinoma (MCC) (7). MCC is rare and aggressive skin cancer predominantly found 
in elderly and immunocompromised individuals. 50% of individuals with advanced 
cases live at least 9 months after being diagnosed with MCC, which is greatly 
reduced in the immunocompromised (7, 131).  Compared to SV40, the genome of 
MCPyV has higher sequence homology to Lymphotrophic polyomavirus (LPyV), a 
polyomavirus isolated in 1979 from a B-lymphoblastoid African green monkey cell 
line. DNA of MCPyV has been detected in the peripheral blood of both healthy and 
immunosuppressed individuals and many other human samples/organs such as: 
eyebrow hairs, gall bladder, oral samples, lung, tonsils, intestine, appendix, liver, 
blood, saliva, lymphoid tissue, urine, malignant and non-malignant tonsillar tissues 
(132-137). Unlike other HPyVs, MCPyV is more closely related to MPyV. 
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Nonetheless, T antigens of MCPyV have the conserved features of the other HPyVs 
including; DnaJ binding domain, OBD, helicase/ATPase domain and conserved pRB 
binding motif (7). The seroprevalence of MCPyV in the healthy adult population 
ranges between 25%-42% (77). MCPyV was initially found integrated into the human 
genome (7). Viral integration into the host genome has also been reported for other 
polyomaviruses that cause tumor in cell culture models, but not before the discovery 
of MCPyV (7).  
3.1.3.3.4 Human polyomavirus 6 and 7 
Two new HPyVs were identified on the skin of adults in 2010 (8). HPyV6 and HPyV7 
were detected by rolling circle amplification (RCA) from forehead swabs of volunteers 
(8). Small amounts of HPyV6 and HPyV7 virions are shed from skin of infected 
individuals. Some initial investigations detected 5/35 people to be positive for HPyV6 
and 4/35 positive for HPyV7. These viruses have been detected in cervical 
specimens of HIV infected and non-infected, malignant and non-malignant tonsillar 
tissues, respiratory samples, feces and urine of an allogeneic stem cell transplant 
recipient. LTag of HPyV7 has been found in 23/37 thymomas (62.2%) and 8/20 
thymic hyperplasia (40%) tissues. Furthermore, HPyV7 have been detected in 
PBMCs and skin of single and double lung transplant recipients with pruritic rash 
(133, 138-140). In addition, both viruses were detected in immunosuppressed 
patients with pruritic and dyskeratotic dermatoses (141). This suggests that these 
viruses can cause disease in immunocompromised patients. Seroprevalence studies 
using VLPs revealed that, HPyV6 and HPyV7 infect 69% and 35% adults, 
respectively, indicating that exposure to these viruses is common (8). So far definitive 
association of these viruses to tumorigenesis is unknown (142). 
3.1.3.3.5 Trichodysplasia spinulosa polyomavirus  
In 2010, another human polyomavirus called TSPyV was detected on the skin by 
RCA (9). TSPyV is the causative agent of Trichodysplasia spinulosa (TS) (9). TS is a 
rare skin disease affecting mostly immunocompromised persons (9, 143). The virus 
together with HPyV9, HPyV12, MCPyV, NJPyV and LIPyV belong to the genus 
Alphapolyomavirus (Fig. 1) (2). The clinical development of TS occurs as an eruption 
of erythematous papules with many follicular extensions localized in the limbs and 
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central face, mostly the nose (144), which was initially reported by Izakovic et al from 
a 31-year-old kidney transplant recipients undergoing treatment with cyclosporine A 
(145). Using quantified PCR and electron microscopy (EM) demonstrated that TSPyV 
was actively infecting TS follicular biopsy (144, 146). It has also been detected in 4% 
of skin swabs from kidney transplant recipients without clinical TS, indicating that this 
virus could be found on the skin without causing disease (9). In addition, this virus 
has been detected in renal allograft of a kidney transplant patient, heart, spleen, lung, 
colon, bronchus, small intestine, liver, respiratory samples, feces, tissue from a 
patient with myocarditis and in tonsillar tissues of healthy individuals (138, 147-149). 
TSPyV has high seroprevalence of about 70% in adult populations (150). This 
supports the theory that infection with this virus is usually asymptomatic causing TS 
only in highly immunocompromised individuals (150). 
3.1.3.3.6 Human polyomavirus 9 
In 2011, HPyV9 was detected in the serum of a kidney transplant recipient using 
degenerate primers (10). Whole genome sequencing of HPyV 9 revealed it to be 
closely related to LPyV and contained all the typical genomic characteristics of a 
polyomavirus (10). LPyV has been detected in blood in both immunosuppressed and 
healthy people and has a seroprevalence of 30% (77, 151, 152). A seroprevalence of 
40% was determined for HPyV9, although cross reactivity of LPyV and HPyV9 was 
confirmed (153). This cross reactivity may account for the previous serological 
evidence of LPyV in human infection (153, 154). HPyV9 has been detected on skin 
swabs of MCC patients. This is in accordance with the finding that in MCC patient 
groups, HPyV9 was more common compared to age-matched controls (154). 
Furthermore, HPyV9 variant was detected in PBMCs of an AIDS patient (155).  
3.1.3.3.7 Human polyomavirus 10 
HPyV10 was discovered in 2012 in chondyloma specimens from a patient with warts, 
hypogammaglobinemia, infections, and myelokathexis-congenital disorder of 
leukocytes (WHIM) syndrome (11, 156). In the same, year a strain of HPyV10 termed 
Malawi polyomavirus (MWPyV) was detected in stool samples of healthy children 
from Malawi using shot gun 454 pyrosequencing (11). Another nearly genetically 
identical strain called Mexican polyomavirus (MXPyV) was detected in stool samples 
 
 
 
25 
of Mexican children (157). MWPyV strain was also found in one respiratory sample 
and stool samples from healthy Mexican children. Furthermore, MWPyV was found in 
tonsils and adenoids of healthy children, whereas HPyV10 was also detected on skin 
of HIV-infected and non-infected men suggesting skin tropism for HPyV10 (157, 158). 
3.1.3.3.8 St Louis polyomavirus 
Like MWPyV, STLPyV was detected in a stool sample from a healthy child in 2013 
using 454 pyrosequencing (12). STLPyV is placed in the genus Deltapolyomavirus 
(2). The virus shows high sequence homology to HPyV6, HPyV7 and HPyV10 in the 
LTag coding sequence (2). STLPyV has been reported to encode a unique protein 
called 229T, obtained through alternative splicing of the EVGR pre-mRNA (18). Stool 
specimens collected from children confirmed the presence of STLPyV, however there 
was no statistical association between STLPyV and gastroenteritis. STLPyV has also 
been identified from a skin wart of a WHIM syndrome patient (12, 159). Compare to 
other HPyVs, STLPyV has a high seroprevalence of about 68%-77%, with age-
stratified data indicating early childhood acquisition of this virus (160). 
3.1.3.3.9 Human polyomavirus 12 
HPyV12 was detected in resected human liver tissues and also in rectum, colon and 
a fecal sample (13). Studies in healthy adults/adolescents and pediatric children 
revealed a seroprevalence of 23% and 17%, respectively (13), indicating that primary 
infection of HPyV12 occurs during early childhood. So far, this virus has not been 
associated with any disease. 
3.1.3.3.10 New Jersey polyomavirus 
NPyV was detected in endothelial cells of a pancreatic transplant recipient suffering 
from necrotic plaques on multiple areas of the skin and retinal blindness (14). High 
viral load and viral particles of NJPyV within the nuclei of vascular endothelia cells 
were detected by specific real time PCR and EM (14). Reduction of 
immunosuppression resulted to slow subsiding of the patient’s weakness, but the 
patient’s eyesight failed to return. NJPyV viremia was detected until 10 months after 
the onset of symptoms, even though the patient showed improvement of symptoms. 
Furthermore, it was not possible to detect NJPyV in sera collected from the general 
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population or in the patient’s pre-transplant serum (14). 
3.1.3.3.11 Lyon IARC polyomavirus  
The most recently LIPyV was discovered from the skin swabs, oral gargles and an 
eyebrow hair of cancer-free individuals by using a sensitive degenerative PCR and 
next-generation sequencing (15). The virus is phylogenetically related to the raccoon 
PyV identified in neuroglial tumors in free-ranging raccoons. The biological properties 
of this PyV is yet unknown. 
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Table 1: HPyVs discovery and potential and proven associated-diseases. N.A: not 
applicable. 
Species/
common 
Name 
Year 
discovered/ 
references 
Initial biological 
compartment 
isolated/detected 
another 
biological 
compartment 
detected 
Associated-diseases 
Seroprevalence
/ references 
BKPyV/ 
HPyV1 
 
1971 (3) 
Urine of kidney 
transplant 
recipient 
Bladder, blood, 
bone, brain, 
CNS, heart lung, 
skin, spleen, 
genital, salivary 
glands 
BKPyV associated- hemorrhagic 
cystitis (BKPyVHC) (96), BKPyV 
associated-nephropathy 
BKPyVVAN) (161), progressive 
multifocal leukoencephalopathy 
(PML) (162), retinitis (162), 
pneumonitis (163) meningitis and 
encephalitis (164), ureteral 
stenosis (165), prostate cancer 
(166), 
55–90% 
(77, 167) 
JCPyV/ 
HPyV2 
 
1971 (4) 
CSF of a PML 
patient 
Brain, CNS, 
kidney, lungs, GI 
tract, blood, 
tonsils 
PML (4),  colon cancer (168),  
multiple sclerosis (MS) (169) 
44-90%  
(77, 167) 
KIPyV/ 
HPyV3 
 
2007 (62) 
Respiratory tract 
secretions 
Blood, stool, 
brain, tonsil, 
CNS, lung 
cancer tissue, 
lymphoid and 
tonsil tissues. 
respiratory disease (18) 55-91%  (77, 118, 170) 
WUPyV/
HPyV4 
 
2007 (6) 
Respiratory tract 
secretions 
Blood, stool, 
brain, tonsil, 
CNS, CSF, 
lymphoid and 
tonsil tissues. 
respiratory disease (171) 
 
69-98% 
(77, 118, 170) 
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MCPyV/
HPyV5 
 
2008 (7) 
Skin of Merkel cell 
carcinoma patients 
Plucked eyebrow 
hairs, healthy 
skin, liver, urine, 
oral samples, 
tonsils, gall 
bladder, lung, 
saliva, oral 
samples 
80% of Merkel cell carcinoma (7)  
58-96%  
(77, 170, 172-
174) 
HPyV6 
 
2010 (8) Human skin swab 
Eyebrow hair, 
stool sample, 
urine, 
nasopharyngeal 
swabs 
BRAF inhibitor-induce epithelia 
proliferations, pruritic and 
dyskeratotic dermatoses (48, 141) 
67–98%  
(8, 170, 172, 
174, 175) 
HPyV7 
 
2010 (8) Human skin swab 
Eyebrow hair, 
stool sample, 
urine, 
nasopharyngeal 
swabs 
Pruritic and dyskeratotic 
dermatoses (48, 141), thymomas 
(139) 
35–86% (8, 
170, 172, 174, 
175) 
TSPyV/ 
HPyV8 
 
2010 (9) 
Skin of 
Trichodysplasia 
spinulosa 
immunocompromi
se patient 
Heart, lungs, 
liver, small 
intestine, colon, 
allograft of 
kidney transplant 
patient, 
bronchus, colon 
tissue, 
Trichodysplasia spinulosa (48)  
70–84%  
(150, 170, 172, 
174) 
HPyV9 
 
2011(10) 
Serum sample of 
kidney transplant 
recipient 
Skin of Merkel 
cell carcinoma 
patient, Skin of 
healthy people 
N.A 
20–70% (153, 
170, 172, 174-
176) 
HPyV10 
 
 
2012  
(11, 157) 
Stool sample 
(MW)/ Condyloma 
specimen (10w) 
Forehead swap, 
stool, respiratory 
samples 
Genital wart, 
Hypogammaglobulinemia, 
infections, Myelokathexis (WHIM) 
syndrome  
(11, 156) 
42–99%  
(170, 177, 178) 
STLPyV/
HPyV11 
 
2013 (12) Stool sample N.A N.A 68–70% (160) 
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3.1.4 Human polyomaviruses and associated diseases 
Most immunocompetent people with a primary HPyV infection have a nonspecific 
influenza-like or subclinical course. However, HPyV can replicate and cause specific 
syndromes in the immunocompromised leading to considerable morbidities. Some 
HPyV-associated diseases are regularly found in specific patient populations. This 
suggests that viral determinants interacting within the patient or organs influence the 
pathological outcome. The reasons for the associations are not clearly understood 
(179). Different pathologies have been associated with HPyV infections. For instance, 
BKPyV has been associated with BKPyV-associated nephropathy, however, its 
association with other diseases such as cancers and autoimmune disease is still 
been disputed. This presents a hurdle in linking some specific pathologies to HPyVs. 
However, a classification of HPyVs-associated pathologies has been described (16, 
161)  
 
 
 
 
 
 
  
HPyV12 
 
2013 (13) Liver 
Colon, rectum, 
stool 
N.A 23–33% 
(13, 175) 
NJPyV/
HPyV13 
 
2014 (14) 
Muscle biopsy of 
pancreatic 
transplant 
recipient 
Muscle’s 
endothelia cells 
and skin 
Vasculitic myopathy in pancreatic 
transplant recipients (14) N.A 
LIPyV 
 2017 (15) 
Skin, eye brown 
hair N.A NA N.A 
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The notions of HPyVs pathologies 
Oncogenic HPyV pathology is characterized by HPyV infecting host cells that allow 
EVGR expression, but insufficient genome replication and LVGR expression to 
permit rapid viral release and host cell lysis. This concept has been clearly described 
in the MCPyV-associated Merkel cell carcinoma, whereby truncation of the LTag 
and/or Vp1 and MCPyV integration into the host’s genome results in the impairment 
of MCPyV genome replication and LVGR expression (7). BKPyV LTag uncoupling of 
host cell activation, LVGR expression and BKPyV release may be associated with 
urothelial cancers (180).  
Cytopathic HPyV pathology is due to rapid viral replication, but with little or no 
inflammation, resulting to cell lysis. This is seen in JCPyV-associated PML due to an 
uncontrolled JCPyV replication in the brain of HIV/AIDS patients. The cytopathology 
is evidence by the loss of the myelin producing cells, leading to neurological deficits 
and disease progression. 
Cytopathic-inflammatory HPyV pathology is characterized by high-level HPyV 
replication and inflammatory response as a result of cell lysis and necrotic infiltrates 
of lymphocytes and granulocytes. This pathological pattern is seen in BKPyV-
associated PyVAN stage B in kidney allografts. 
Immune-reconstituting inflammatory syndrome (IRIS) HPyV pathology is due to high 
inflammatory response to HPyV antigens, usually during a hasty recovery of the 
cellular immune response (161, 181). The prototypes are JCPyV-associated PML, 
which worsen after the commencement of highly active antiretroviral therapy (HAART) 
(182) or following removal of natalizumab from the plasma in multiple sclerosis 
patients (183). 
Autoimmune HPyV pathology characterized by responding to ’self’ which may be 
provoked by HPyV antigens. For instance, PyV-LTag interaction with histones and 
DNA may trigger antibodies against histones or DNA (184-186).  
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Fig. 6: Proposed pattern of HPyV disease during the course of viral replication and 
immune response adapted from (161). HAART; a colon (:) represents interaction; 
BMT, bone marrow transplantation; BKPyVAN-A and BKPyVAN-B, BKPyVAN 
patterns A and B. 
BKPyV, JCPyV, MCPyV, TSPyV and HPyV7 are known to cause diseases in 
humans (3). Moreover, HPyV6 have been linked to certain diseases (48, 141), while 
other HPyVs, such as HPyV10 and NJPyV were initially detected from diseased 
specimens or patients (11, 156) .  
3.1.4.1 Human polyomaviruses associated non-cancerous diseases 
3.1.4.1.1 BKPyV-associated diseases 
 
Polyomavirus associated nephropathy (PyVAN) 
BKPyV was associated with PyVAN in renal transplant recipients. Approximately 1%-
10% of kidney transplant recipients progress to PyVAN and up to 90% of these 
patients lose their allograft (187-189). PyVAN is a type of acute interstitial nephritis 
(190) characterized by denudation of the basement membrane (Fig. 7A) and 
necrosis of the proximal tubules due to BKPyV lytic infection and replication in kidney 
epithelial cells (191). The introduction of new and more potent immunosuppressive 
drugs suggests a relationship between immune surveillance disruption and BKPyV 
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reactivation (189, 192, 193). Currently, PyVAN diagnosis includes renal biopsy 
analyses by immunohistochemistry (IHC) (Fig. 7B) or histopathology to either 
determine cytopathic effects as a result of lysis of renal tubular epithelia cells. In 
addition, cytology of urine can be performed to detect decoy epithelial cells, which 
contain intranuclear viral inclusion bodies and PCR to detect and quantify viral load in 
urine or blood samples (194, 195).  Urine cytology and PCR could be useful for early 
detection of reactivation and PyVAN (187), thus permitting faster diagnosis and 
intervention with a consequential increase in graft survival (196). 
The risk factor for PyVAN is unclear, however combination of contributing factors 
from the virus, patient and graft determine the susceptibility to BKPyV. The major risk 
factor to PyVAN is suggested to be due to an overall degree of immunosuppression 
and not a particular immunosuppressive treatment (197, 198). More so, the 
development of PyVAN is not dependent on immunosuppression alone, since the 
manifestation of the disease is relatively uncommon in non-renal solid organ 
recipients and other immunosuppressed individuals (161). Furthermore, specific 
human leukocyte antigen (HLA) mismatches or donor seropositive, older age and 
male gender are all potential risk factors (187, 199-201). 
Until now, there is no specific and effective BKPyV anti-viral treatment available. 
Nonetheless, decreasing immunosuppression to permit the immune system to regain 
control over the infection is the most common first line intervention, although may not 
be effective in all patients, and may expose the patient to a potential risk of acute 
graft rejection. Cidofovir, an antiviral nucleoside analogue, inhibits BKPyV DNA 
replication in vitro (202), but it is nephrotoxic at high doses (203). Studies revealed 
that at low doses and combined with the reduction of immunosuppression, Cidofovir 
can be effective in preventing BKPyV reactivation without causing significant 
nephrotoxicity (204-207). Additionally, the immunosuppressive drug leflunomide has 
shown some limited successes (207-209). Other antiviral treatments are 
fluoroquinolone antibiotics and intravenous immunoglobulin (IVIG) (197, 210-212). 
More detailed studies are required to evaluate the efficacies of these drugs. Lastly, 
rapid clearing of the viral source after nephrectomy and then re-transplantation could 
be another treatment approach. 
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Fig. 7: BKPyV nephropathy (213). (A) Periodic acid Schiff stained section showing 
tubular epithelia cells with intranuclear viral inclusion bodies (arrows). (B) 
Immunohistochemistry (IHC) showing a formalin fixed and paraffin embedded tissue 
section showing BKPyV LTag staining (brown color) with SV40 LTag antibody, which 
cross reacts with BKPyV LTag. 
Polyomavirus-associated hemorrhagic cystitis (PyVHC)  
BKPyV is also associated with PyVHC affecting 10%-25% of bone marrow transplant 
(BMT) patients  (214). The disease is probably due to BKPyV reactivation in possibly 
urothelial cells and renal tubular epithelia cells, resulting in high-level BKPyV 
replication due to lack of immune surveillance. Furthermore, there is prominent 
denudation of the cell’s basement membrane, leading to hemorrhage and 
inflammation (215). The disease is characterized by flank pain, dysuria with or 
without signs of insufficiency. Additionally, it can be associated with varying grades 
(grades I-IV) of hematuria (215). A classical BKPyV-associated PyVHC occurs after 
more than 10 days post-transplantation. PyVHC is not life-threatening, but associated 
with significant morbidity (216-219). The most commonly applied diagnostic methods 
for BKPyV-associated PyVHC are PCR detection of viral DNA, IHC to detected LTag 
expression (Fig. 8A) and urine cytology for the detection of decoy epithelia cells (Fig. 
8B) (220). Other sophisticated-diagnostic methods include; magnetic resonance 
imaging (MRI) or computer tomography (CT) to evaluate the bladder features. The 
bladder features in infected patients is characterized as; bladder wall thickening, 
increase mucosa enhancement, mural edema, small bladder capacity and 
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intraluminal clot (221). Like PyVAN, reduction of immunosuppression can be used as 
a treatment option for PyVHC, whereas exogenous BKPyV-specific T-cell application 
is being investigated as future therapies (214). Furthermore, antivirals including 
fluoroquinolone antibiotics, leflunomide, mTOR inhibitors and cidofovir are currently 
being evaluated for efficacy in treating BKPyV-associated diseases (222-225).  
 
 
 
 
 
 
Fig. 8: (A) Bladder biopsy from a patient with PyVHC (www.pathology.mc.duke.edu) 
depicting denudation and BKPyV infected cells (red arrow head) with enlarged 
nucleus. (B) PyVHC (220), depicting the characteristic BKPyV-infected cells with 
decoy cells (arrow) showing enlarged nucleus containing a large intranuclear 
inclusion BKPyV-associated diseases. 
 
Progressive multifocal leukoencephalopathy (PML) 
 
JCPyV is associated with PML affecting the immunocompromised due to HIV/AIDS, 
cancer, transplantation and treatment of multiple sclerosis patients with Natalizumab 
(4, 226-228). A high activity of JCPyV IgG activity is speculative of recent infection 
with JCPyV, and indicative for an increased risk for PML development in AIDS 
patients (229). Initially, PML was considered to be a very rare disease associated 
with immunocompromised patients, usually those with leukemia and lymphomas (93). 
With the rise of the HIV/AIDS epidemic, PML resulting from JCPyV infections have 
drastically risen. Up to 85% of PML cases occur in AIDS patients (230, 231), since 
not all AIDS-affected patients or even those with very low CD4+ T cells counts come 
down with PML (232). However, only few sporadic PML cases develop without an 
underlying immunosuppression (233). In essence, PML is now regarded an AIDS-
defining disease (93).  
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PML is clinically characterized by dementia or confusion, speech and vision 
impairment, varying degree of akinesia or paralysis, in concurrence with 
immunosuppression and lack of increase in intracranial pressure (94, 233). The 
progression to PML disease is rapid, with clinically-intensifying symptoms and death 
within 3-6 months (234), which has however, been improved with the introduction of 
high-active anti-retroviral therapy (HAART) (235). With respect to the cellular level, 
PML results as lysis of oligodendrocytes, the myelin producing cells of the brain, 
leading to lesion in the brain stem, cerebellum and cerebrum and especially along 
the white and gray matter junction (Fig. 9A) (236, 237). JCPyV DNA sequences have 
been detected in mononuclear cells and B cells within the brain (238, 239). Enlarged 
JCPyV Tag-expressing oligodendrocytes with crystalline arrays of viral particles (Fig. 
9B) and nuclear inclusion bodies are other features of PML (230, 231). The high 
frequency of JCPyV-positive PBMCs and widely distributed brain lesions indicate that 
lymphocytes can serve as a reservoir and a dissemination vehicle (231, 240, 241). 
Whether JCPyV infection of the brain is as a result of reactivation of latent infection 
or de novo invasion of the virus is unclear (81, 242). 
The association between PML caused by JCPyV and HIV/AIDS is not clearly 
understood. However, the link between these two virus-associated disease could be 
explained by several hypotheses (230, 243, 244). Firstly, HIV establishes a thorough 
immunosuppression in the host by decreasing JCPyV-specific CD4+ T-cells leading 
to an uncontrollable JCPyV replication. Specifically, infection of HIV may cause break 
down of the blood-brain barrier, permitting entry of JCPyV-harboring B cells into the 
brain. Furthermore, certain cytokines produced as a result of HIV infection could 
initiate cell signaling events that may activate the JCPyV promoter. Lastly, the HIV 
Tat protein may activate JCPyV promoters in vitro and increase gene expression 
(245). Currently, there is no specific antiviral drug to treat PML. However, clinicians 
now focus on immune reconstitution-based concept.  
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Fig. 8: (A) T2-weighted image of brain from patient with PML (246). The image 
shows multiple hyper-intense subcortical lesions in the left hemisphere (arrows). (B) 
Particle of JCPyV in PML lesion (226). Viral particles (VP) scattered all over major 
areas of the nucleoplasm. Arrows indicate nuclear membrane, while C shows nuclear 
chromatin. 
 
JCPyV-associated PyVAN 
 
The first case of JCPyV-associated PyVAN was identified in a 15-year old with 
kidney transplantation (247). Kidney biopsy from the patient stained positive for LTag 
(Fig. 10) and quantitative PCR revealed high JCPyV load in the urine (247). 
Generally, JCPyVAN is found in approximately 1% of kidney transplant patients (248) 
and about 6% of HIV patients present with JCPyV replication in the kidney (249). 
Most patients with JCPyVAN have normal kidney function indicating that JCPyV has 
a more protracted course or it is apparently less aggressive compared to BKPyVAN. 
In addition, BKPyVAN and JCPyVAN have another difference based on the severity 
of the histological pattern and strong viremia associated with BKPyVAN (187). 
Conversely, patients shedding large amounts of JCPyV in urine or patients with 
parenchyma involvement have been reported to show low viremia levels. This could 
be due to the basic differences between the biology of JCPyV and BKPyV, which has 
not been resolved in detail (250, 251). With the debilitating diseases caused by 
JCPyV and BKPyV, there is an urgent need for the development of specific antiviral 
therapies. 
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Fig. 10: Kidney allograft biopsy stained positive for LTag using SV40 LTag antibody 
which cross reacts with JCPyV LTag. 
 
3.1.4.1.2 TSPyV-associated disease 
 
Trychodysplasia spinulosa 
 
TSPyV was initially detected in plucked facial spines from an immunosuppressed 
patient with a rare skin disease called Trichodysplasia spinulosa (TS) (9). 
Development of the disease may be due to uncontrollable replication of TSPyV in the 
inner root sheath cells. Analysis of the lesions by EM consecutively showed 
regularly-spaced 38-45nm intranuclear, crystalloid-organized viral particles (144). 
The disease is characterized by reddened flesh-colored papules often centrally 
located in the face and other places of the body, usually with spines made of keratin 
(Fig. 11). TSPyV has been exclusively reported in the immunocompromised 
including patients with acute lymphocytic leukemia patients and solid organ 
transplant recipients (143, 252, 253).  
TSPyV is diagnosed by histopathological examination of biopsies from lesioned skins 
showing enlarged hair follicles with perinuclear globules of the inner root sheath cells 
and evident eosinophilia. Additionally, TSPyV DNA and viral load is measured by 
quantitative PCR (qPCR). So far, all TS lesioned samples were positive for TSPyV 
with a high viral load ranging between 104-107 genome copies per cell (9, 144). 
Occasionally, samples from normal skin of TS patients, plucked eyebrow hairs and 
skin swabs from unaffected people were TSPyV DNA-positive with a viral load of 
below 100 copies per cell (9, 144). There is evidence that TS is caused by TSPyV (9, 
144, 252). There is no antiviral treatment available for TS. However, restoring the 
immune function in immunocompromised patients resulted in complete resolution of 
TS symptoms, although with a higher risk of graft rejection. Significant reduction of 
TS symptoms has been revealed in a number of TS patients treated with 1%-3% 
cidofovir cream (144). In addition, oral valganciclovir, a guanosine analog, showed a 
modest effect in some TS patients (144). The exact mechanism of action of these 
drugs is yet to be elucidated. 
 
 
 
38 
 
 
Fig. 11: Features of TS (9). The nose of a patient suffering from TS with numerous 
papules and spicules. 
 
Potential diseases associated with novel HPyVs 
 
DNA sequences of novel HPyVs, such as HyPV6, HPyV7, HPyV9, HPyV10, HPyV12 
and NJPyV, were detected in patient’s samples, but not much is known with respect 
to their potential disease-causing role in humans (7, 10, 13, 14, 156). On the other 
hand MCPyV is associated with a malignant disease, MCC (reviewed below) (7). 
Furthermore, KIPyV and WUPyV are detected mostly in respiratory secretions from 
patients with respiratory diseases, but so far the association of these viruses with 
respiratory diseases is unclear due to co-detection with other respiratory viruses 
(254). Nonetheless, high-throughput sequencing of isolated RNA from a nasal swab 
sample from a healthy and a one-month-old boy with severe respiratory symptoms 
revealed transcripts of KIPyV, whereas sequences of other viruses were not detected, 
except of few reads from human Boca virus (18). This indicates a potential role of 
KIPyV in respiratory pathogenesis. On the other hand, WUPyV may also cause 
respiratory pathogenesis due to a reported case of WUPyV associated with 
bronchitis (18). HPyV6 and HPyV7 are chronically shed from the skin (8). Both 
viruses have been reported to be associated with dyskeratotic dermatoses and 
pruritic rash in immunosuppressed patients (141, 255). The patients´ skin infection 
demonstrated brown plaques, scales and pruritus with a characteristic parakeratosis 
pattern (peacock plumage) (141, 255). More so, the skin biopsies presented with 
characteristic patterns of parakeratosis and dyskeratosis, which revealed abundance 
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of viral capsid, Tag, higher viral load compared to healthy skin and intact viral 
particles (141). HPyV6 DNA has been detected in epithelial neoplasms and the 
involvement of HPyV6 in the neoplasms cannot be excluded (256).  Additionally, 
DNA of HPyV6 has been found in the CSF of an HIV/AIDS patient with PML (257) 
and in lymph nodes of a 51-old woman having angiolymphoid hyperplasia with 
kimura disease or eosinophilia (18). A hematopoietic stem cell transplant patient was 
diagnosed with HPyV7 viruria (18). Whether these viruses are associated with the 
above diseases is left to be determined. The small sample size was the major 
limitation to the above case reports. Probably, larger case control studies would shed 
more-light on disease-association of these viruses.  
3.1.4.2 Human polyomaviruses and cancers  
Since 1953, when MPyV was demonstrated to cause tumors in newborn mice, 
polyomaviruses have been suspected to be an etiologic agent of cancers. The role of 
SV40 as an etiological agent of cancer has been debated intensively. SV40 has been 
reported to induce tumors in animal models, transform human cells and detected in 
many human tumors. Moreover, epidemiological studies failed to show significant 
seroconversion in the human population  (258, 259). Polyomaviruses associated-
oncogenesis has been solely attributed to the LTag (28, 260, 261). LTag can interact 
with tumor suppressor proteins pRB, p107, p130 and p53, to interfere with cellular 
processes such as protein degradation, transcription, DNA repair, telomerase activity, 
stimulates angiogenesis, apoptosis and cell migration (260, 262). Interaction with p53 
and retinoblastoma proteins required the C-terminal domain and the conserved 
LXCXE motif. MCPyV-derived MCC cells express LTag with a C-terminal truncation 
of the p53 binding domain, indicating cellular transformation by MCPyV is 
independent on p53. (263). Moreover, the sTag may also contribute to transformation 
by inactivating PP2A, and thus activating anti-apoptotic and proliferating pathways, 
and enhancing oncogenesis (18, 260, 264). The interaction of sTag with PP2A 
depends on the conserved motif, CXCX2C motif. This PP2A binding motif is 
conserved in all polyomaviruses (177, 265, 266), but whether this motif bind PP2A in 
all polyomaviruses is left to be tested. One could suggest that, polyomaviruses are 
potential oncoviruses, since they all encode the oncogenic proteins, LTag and sTag 
(Fig. 3).  However, avian polyomaviruses which also encode LTag and sTag do not 
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seem to induce tumors, which could be due to the lack of the pRB consensus binding 
sequence (LXCXE) found in the LTag of mammalian polyomaviruses (28, 267). Cell 
culture studies reported agno detection in cancers and the probable contribution of 
agnoprotein to tumorigenesis (261, 268).  
 
3.1.4.2.1 MCPyV-associated Merkel cell carcinoma 
 
Out of the 14 HPyVs, MCPyV is in fact the only HPyV possibly associated with 
human cancer  (7, 269). This virus is associated with about 80% of MCC (7, 269). 
MCC is a cutaneous tumor cause mostly by MCPyV. Cyril Toker was the first to 
described MCC in 1972 (270). He found a bluish-red or flesh-colored glassy painless 
nodule (Fig. 12) having solid trabeculae in 5 different places (lip, face, leg, forearm 
and buttock) of 2 elderly men, who died due to the tumors, and 3 elderly women 
(270). The name trabecular carcinoma of the skin was used by Toker to described 
these tumors, thinking that they depict an endocrine carcinoma of the sweat gland 
(270). MCC is classified as a group 2A carcinogenic biological agents (271). 
Epidemiological data revealed that this disease is affecting elderly people,  
 
 
 
fair-skinned persons or the immunocompromised (270, 272, 273). More than 90% of 
MCC lesions are commonly found in sun-exposed areas, with half in the face, neck 
or extremities, it can also occur in perianal region, truck and genitalia although at a 
significantly reduced frequency (<10%) (270). The origin of primary MCC is unknown. 
However, the origin is thought to occur in Merkel cells, which is a type of 
mechanoreceptor cells found in the stratum basale in the epidermis. Excluding 
Merkel cells, the disease has also been suggested to originate from skin-derived 
precursors, and epidermal and dermal stem cells (274). Truncation of MCPyV LTag 
in MCPyV-positive MCC, promotes oncogenic transformation of MCPyV (275). The 
oncogenic potentials of MCPyV to other tumors have been extensively reviewed and 
documented in animal models and cell culture systems (48, 87, 91, 130, 134, 261, 
263, 276-278). Moreover, the virus was not detected in squamous cell carcinoma or 
keratoacanthoma (279). Furthermore, MCPyV DNA was investigated in 10 small cell 
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lung carcinoma patients and 5 MCC patients, but was only detected in 2/5 MCC 
patients (280). In addition, investigation of MCPyV roles in 30 lung carcinomas, 28 
prostrate samples and 25 childhood brain tumors revealed no evidence of MCPyV in 
these cancers (129, 281). More so, MCPyV DNA was found in 10 MCCs from a study 
with 1241 tumors (282). However, MCPyV was not found in ovary, breast, bone, 
melanoma, basal cell carcinoma, soft tissue, uterine cervix and large bowel cancers 
(282). These suggest that MCPyV has no roles in the oncogenesis of other cancers 
except MCC. Furthermore, the role of MCPyV in MCC is complimented with the fact 
that MCC is dependent on Tag expression and patients with MCC, usually 
demonstrate very high levels of MCPyV antibody titters compared to the general 
population, suggesting that infection of MCPyV is associated with MCC.  
Presently, MCC is treated by using the following therapeutic strategies; 
chemotherapy, radiotherapy or surgery with little effect in the setting of metastasis 
(283). An immunotherapy based on programmed death 1 (PD-1), revealed good 
response in MCC patients with and without MCPyV DNA detection (284). Lastly, 
probable MCC prevention could be via a MCPyV VP1-based vaccine (285). The 
need for specific anti-viral treatment for MCPyV is warranted.  
 
 
 
Fig. 12: Merkel cell carcinoma nodule on the leg of a patient (270). 
 
The oncogenic potentials of JCPyV, BKPyV with tumors have been extensively 
reviewed and documented in animal models and cell culture systems (48, 87, 91, 130, 
134, 166, 261, 263, 276-278). BKPyV and JCPyV are classified as a group 2B 
carcinogenic biological agents with possible carcinogenicity to humans (286). The 
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DNA, RNA, and proteins of BKPyV and JCPyV have been detected in many tumor 
tissues, but also in control non-cancer tissues (87, 91, 130). Thus, the potential role 
of BKPyV and JCPyV in human tumors is controversial. The presence of JCPyV in 
colorectal and CNS tumors may increase the risk of getting the tumors, while BKPyV 
may be associated with prostate and renal tumors (166, 278, 287). Harald zur 
Hausen, suggested that JCPyV-associated colorectal tumors may be due to other 
polyomaviruses consumed in meat (288). Several bovine polyomaviruses related to 
MCPyV, HPyV6, HPyV7 and other mammalian PyVs have been identified in beef 
samples (289, 290). Thus far, these viruses have not been detected in human 
colorectal biopsies. The association of novel HPyVs with cancers have been scarcely 
reported with only a few cases where DNA or protein of some novel HPyVs have 
been detected in tumor tissues (Table 2). Based on the current knowledge, 
convincing evidence of the role of HPyVs excluding MCPyV in tumorigenesis is 
lacking  (28, 171). 
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Table 2: Prevalence of novel HPyVs in human cancers, adapted from (28). 
Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH). 
 
Tumors Number of 
samples 
Method Number of positive 
samples with HPyVs 
References 
Melanoma 18 PCR and 
IHC 
HPyV6: 18, HPyV7: 
17, TSPyV: 4, HPyV9: 
1, HPyv10: 12 
(256) 
Squamous cell 
carcinoma (SCC) 
63 PCR HPyV6: 2, HPyV7: 1 (291) 
Basal cell carcinoma 50 PCR HPyV6: 2, HPyV7: 2 (291) 
Melanoma 47 PCR HPyV6: 2, HPyV7: 2 (291) 
Basal cell carcinoma 41 PCR HPyV6: 3 (292) 
SCC 52 PCR HPyV6: 2 (292) 
SCC in situ 8 PCR HPyV6: 1 (292) 
Keratoacanthoma 42 PCR HPyV6: 2 (292) 
Actinic keratosis (AK) 31 PCR HPyV6: 1 (292) 
Breast cancer 54 PCR HPyV6: 1, HPyV7: 1 (293) 
Merkel cell carcinoma 1 Deep 
sequencing 
HPyV6: 1, HPyV7: 1, 
HPyV9: 1 
(294) 
SCC AK 142 Deep 
sequencing 
HPyV6: 1 (295) 
Primary cutaneous B-cell 
lymphomas 
130 PCR HPyV6: 6, HPyV7: 1 (296) 
Lung cancer 20 PCR KIPyV: 9 (128) 
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Skin lesions from 
cutaneous T-cells 
lymphomas patients 
39 PCR HPyV6: 11, HPyV7: 5 (297) 
Thymic epithelia tumours 37 PCR, 
FISH, IHC 
HPyV7: 23 (139) 
Thymic hyperplasias 20 PCR, 
FISH, IHC 
HPyV7:  14 (139) 
 
3.1.5 Systems for HPyV propagation and infection 
Bacterially expressed Vp1 pentamers represent the smallest in vitro model used for 
studying viral entry. Pentameric subunits of Vp1 have been successfully used to 
recapitulate early events of TSPyV and JCPyV life cycle, such as structural studies of 
Vp1-receptor complexes, receptor specificity, as well as intracellular trafficking routes 
(298-300). Vp1 of PyV can be self-assembled into VLPs (301, 302). Baculovirus and 
yeast expression systems have been used to produce PyV VLPs (302). These VLPs 
were applied in PyV seroprevalence rates screenings (19, 301, 303, 304). Pseudo-
viruses (PsVs) have been used for the analysis of PyV primary host cell tropism, 
such as viral attachment and entry. They are produced by co-transfection of 
mammalian cell lines such as HEK293TT (293TT) with expression vectors encoding 
PyV capsid proteins and vectors that encode a reporter protein, such as red 
fluorescent protein (RFP), green fluorescent protein (GFP) or Gaussia luciferase. 
This allows vivid quantification of the PsV in the target cells. Although these systems 
are important in revealing PyV’s primary host cell tropism, the cellular factors 
required for viral expression and replication in the host cells cannot be analyzed 
using VLPs or Vp1 pentamers, since they lack the promoter of the virus which 
determines secondary host tropism.  
So far, only BKPyV and JCPyV can be efficiently replicated in cell culture (305). 
Efficient propagation of archetype and rearranged variants of BKPyV and JCPyV 
have been conducted in the 293TT human embryonic kidney cell line (306). Viral 
replication, late protein expression and production of viral progeny were 
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demonstrated following transfection of episomal HPyVs DNA in 293TT cells. The 
293TT cells carry an integrated plasmid encoding the cDNA of the SV40 LTag and a 
copy of the SV40 whole genome (307). The cell line constitutively expresses the 
SV40 LTag, which drives BKPyV and JCPyV DNA replication from their ori, but failed 
to significantly support replication from the ori of KIPyV, WUPyV and MCPyV. The 
successful replication of BKPyV and JCPyV in 293TT could be due to the fact that 
SV40 T antigens coding sequences have higher similarity to the BKPyV and JCPyV 
T antigens than the T antigens of KIPyV, WUPyV and MCPyV (306). Although large-
scale propagation of BKPyV and JCPyV could be attained in these 293TT cells, this 
cell line is not a suitable model for the study of HPyVs` life cycle, since it has been 
transformed. Presently, to study BKPyV in vitro infection, human renal proximal 
tubule epithelial cells (RPTEC) are used as the state-of-the-art model. Nevertheless, 
the proliferative potential and the experimental design are restricted, since RPTECs 
could enter into replicative senescence. Rearranged BKPyV variants have been 
reported to replicate in a broad range of different cell lines including brain and 
melanoma cancer cell lines, monkey kidney cell lines (Vero and CV-1 cell lines) and 
human ovarian (302, 308, 309) and salivary gland cells (85, 86, 308). JCPyV has a 
major tropism in vivo for glial cells, while productively infecting oligodendrocytes and 
astrocytes to a lesser extent (85, 310). JCPyV infection has been mostly studied in 
the human fetal glial cell line, SVG which constitutively expresses SV40 LTag (311). 
A subpopulation of SVG p12 cells provided by ATCC has been reported by 
Henriksen et al., (312) to be productively infected with BKPyV (312). A subclone of 
the original SVG human glial cell line, SVG-A cells, which do not contain BKPyV, can 
be used as an alternative (312). Furthermore, efficient replication of JCPyV 
archetype and rearranged variants has been reported in Cos-7 which is a CV-1 cell 
line transformed with SV40 origin-defective mutant (311, 313).  
MCPyV have been reported to be propagated in 293-4T cells, a 293TT cell line co-
transfected with plasmids expressing MCPyV sTag and LTag (314). In addition, 
replication of MCPyV in HEK293 cells stably expressing MCPyV sTag or LTag only 
has also been reported (315). These results suggest that expression of specific T 
antigens is a limiting factor for HPyV propagation, thus specific T antigens expressing 
cells could be used as PyV-permissive cell culture systems for other unculturable 
HPyVs. Moreover, MCPyV have been replicated in cell lines not expressing MCPyV 
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T antigens such as, H1299 (human non-small cell lung carcinoma cell line) and 
PFSK-1 (neuroectodermal tumor cell line)  and in HEK293 cells, but without serial 
infection (315, 316). This indicates that these cell lines contain the required 
transcription factors necessary for MCPyV replication, but lack the necessary 
receptor(s) and co-receptor(s) for attachment and entry. 
The host cells naturally infected by HPyVs are so far unknown with the exception of 
MCPyV whose natural host cell has been demonstrated to be human dermal 
fibroblasts (317). Animal models to study HPyV infection are hampered by the narrow 
host range and cell specificity of HPyVs. For instance, JCPyV inoculation of hamsters 
or mice resulted in tumor formation, but failed to recapitulate the JCPyV 
demyelinating disease present in humans (318). To date, small animal models 
available for HPyV infection include humanized mice, xenografts, infectious mouse 
PyV models and transgenic mouse models (305). Available culture systems have 
focused mainly on the propagation of BKPyV and JCPyV with the focus on 
understanding the primary host cell tropism, that is receptors and co-receptors for 
JCPyV and BKPyV attachment and entry (319-321). Furthermore, most studies used 
PsVs and Vp1 pentamers, which lack important components of the viral genome. The 
study of viral attachment and entry receptors is important, but cellular and viral 
factors that interact with the HPyV-NCCRs will determine the secondary host cell 
tropism and potential host cells for HPyVs propagation.  
The NCCR of HPyVs defines the secondary host cell tropism and is critical for all 
HPyVs biology (persistence, latency, reactivation). The activity of HPyV-NCCRs, 
especially those of novel HPyVs in cell culture is scare, whereas that of BKPyV and 
JCPyV have been frequently analyzed. Examining the NCCR activity of novel HPyVs 
in cell culture will shed lights on HPyVs cell tropism and cell lines where they could 
be productively replicated. The genome of HPyVs are similar however, the HPyV-
NCCRs are different with respect to length, LTAg-binding sites and TFBS. NCCR 
rearrangement has been studied in detailed for the BKPyV and JCPyV, and less for 
the novel HPyVs. Therefore, understanding the effect of HPyV-NCCR rearrangement 
in novel HPyVs, and the detailed mechanistic role of Sp1 binding sites and LTag-
binding sites in the regulation of EVGR and LVGR expression, would go a long way 
in deciphering possible avenues for therapeutic strategies against the growing family 
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of HPyVs. The role of Sp1 and LTag-binding motif on EVGR and LVGR expression 
were investigated in BKPyV ww as a model, which can be extrapolated to other 
HPyVs with similar Sp1 and LTag-binding sites organization. 
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4 AIMS OF THE THESIS 
The aims of the thesis are: 
1. Compare the NCCR activity of the 13 known HPyVs in different host cell lines 
with respect to EVGR and LVGR expression. 
2. Characterize the effect of exogenous LTag expression in HPyVs EVGR and 
LVGR expression.  
3. Characterize the effect of different host cell lines on EVGR and LVGR 
expression. 
4. Examine the role of predicted LTag-binding motif in the BKPyV ww NCCR with 
respect to EVGR and LVGR expression. 
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4.1 Hypotheses 
Question 1 
 
Are there differences in HPyV-NCCRs activity with respect to EVGR and LVGR 
expression in the same host cells? 
 
H1: There are differences when present in the same host cell. 
 
H0: The are no differences.  
 
Approach  
We used a bi-directional reporter vector to analyze the NCCR-driven EVGR and 
LVGR expression of the 13 HPyVs in HEK293 as a reference cell line. 
 
Interpretations 
- The HPyV-NCCRs which differ in length and TFBS will sense and interpret the 
same host cell’s transcription factors make-up to drive gene expression.  
- The HPyV-NCCRs may have the same activity in the same host cells. 
 
Caveat: The techniques used may not be sensitive enough to measure differences. 
 
Question 2 
 
Are there differences in HPyV-NCCRs activity with respect to EVGR and LVGR 
expression in different host cells? 
 
H1: There are differences when present in different host cells. 
 
H0: The are no differences.  
 
Approach 
We used the bidirectional reporter vector to analyze the NCCR-driven EVGR and 
LVGR expression of the 13 HPyVs in different cell lines. 
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Interpretations 
- The HPyV-NCCRs which differ in length and TFBS will sense and interpret 
different host cells’ transcription factors make-up to drive gene expression.  
- The HPyV-NCCRs may have the same activity in the different host cells. 
 
Caveat: The techniques used may not be sensitive enough to measure differences. 
 
Question 3 
 
Does SV40 T-antigens have effects on HPyV-NCCRs driven EVGR and LVGR 
expression? 
 
H1: SV40 T-antigens have effects on HPyV-NCCRs driven EVGR and LVGR 
expression. 
 
H0: SV40 T-antigens have no effect on HPyV-NCCRs driven EVGR and LVGR 
expression 
 
Approach 
We examined the effect of T-antigens on the EVGR and LVGR expression of HPyVs 
in HEK293-derivative cell lines that constitutively expressing SV40 sTag and LTag. 
 
Interpretations 
- The HPyV-NCCRs which differ in number and organization of LTag-binding 
sites will sense and response to SV40 T-antigens. 
- The HPyV-NCCRs may not response to SV40 T-antigens. 
 
Caveat: Our techniques used may not be sensitive enough to measure HPyV-
NCCRs’ response to SV40 T-antigens. 
 
Question 4 
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Does SV40 T-antigens have different effects on HPyV-NCCRs driven EVGR and 
LVGR expression? 
 
H1: SV40 T-antigens have different effects on HPyV-NCCRs driven EVGR and 
LVGR expression. 
 
H0: SV40 T-antigens have the same effect on HPyV-NCCRs driven EVGR and 
LVGR expression. 
 
Approach 
We examined the effect of T-antigens on the EVGR and LVGR expression of HPyVs 
in HEK293-derivative cell lines that constitutively expressing SV40 sTag and LTag. 
 
Interpretations 
- The HPyV-NCCRs which differ in number and organization of LTag-binding 
sites will sense and response to SV40 T-antigens differently. 
- The HPyV-NCCRs may response the same to SV40 T-antigens. 
 
Caveat: Our techniques used may not be sensitive enough to measure the difference 
in HPyV-NCCRs’ response to SV40 T-antigens. 
 
Question 5 
 
Does mutageneses of LTag-binding sites of BKPyV-NCCR have an effect on EVGR 
and LVGR expression in HEK293 cells and HEK293-derivative cell lines that 
constitutively expressing SV40 LTag in different amounts? 
 
H1: There is an effect on EVGR and LVGR expression. 
 
H0: There is no effect on EVGR and LVGR expression. 
 
Approach 
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We used the bi-directional reporter to compare the BKPyV ww NCCR-driven EVGR 
and LVGR expression to designed BKPyV ww NCCR defective in one or more LTag-
binding sites. 
 
Interpretations 
- The number and position of LTag-binding sites will affect the NCCR-driven 
EVGR and LVGR expression. 
- The number and position of LTag-binding sites has no role with respect to 
EVGR and LVGR expression 
 
Caveat: Our techniques might not be sensitive to measure the EVGR and LVGR 
expression of the different LTag-binding site mutants. 
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4.2 Rationales 
Increasingly, the HPyVs are considered to be emerging opportunistic viruses. Very little 
is known about the basic biology of these viruses, especially the newly discovered 
HPyVs. Information on the route of transmission, associated diseases, medical 
treatment, life cycle, viral gene regulation, cell tropism and replication in cell culture are 
lacking. Furthermore, the NCCR activity which can be used as an indicator of HPyV cell 
tropism and replication in cell culture is lacking for the newly discovered HPyVs. 
Propagation of these viruses in cell culture is scarce; only BKPyV and JCPyV can be 
efficiently replicated in cell culture. Nonetheless, many cell culture studies have focused 
on the mechanisms of HPyV primary host cell entry by using Vp1 pentamers, VLPs and 
pseudoviruses, which do not include all aspects of the viral replication cycle. Although 
primary host cell tropism is important, cellular factors or early viral proteins that interact 
with the NCCR will affect viral expression and replication, thus determining the 
secondary host cell tropism. The NCCR of HPyVs functions as a bi-directional promoter, 
regulating the EVGR and LVGR expression and determining the permissiveness of 
HPyVs in their host cells. Analyzing NCCR activity of the 13 HPyVs, the roles of LTag 
and Sp1 binding motif with respect to EVGR and LVGR expression, would throw lights 
on the basic biological aspects of HPyVs, help in the development of cell culture 
systems for propagating HPyVs, identification of cell tropism and open avenues for new 
therapeutic approaches for eliminating these viruses, especially in the context of 
immunosuppression.  
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5 RESULTS 
5.1 Designing a smaller bi-directional reporter vector lacking some 
sequences compared to the previous pHRG reporter vector 
 
Transfection of large plasmids has been reported to have lower efficiency than small 
ones in human cell lines. We designed a new-smaller bi-directional reporter pRG13 
recapitulating the HPyV genome (Fig. 1A) based on the phRG reporter described in 
Gosert et al. (25). Compared to phRG (25), the reporter lacks the beta globulin 
polyadenylation signal, Hygromycin gene and an SV40 early promoter, which could 
compete with the NCCR. The late leader sequence encoding the agno protein of 
JCPyV has been reported to contain potential regulatory elements. Deletion or 
mutagenesis analyses of this sequence significantly decreased EVGR expression 
and thus viral replication (322). Furthermore, clinical BKPyV variants with agno gene 
deletion have been identified to be non-functional (323). PhRG and the newly 
designed pRG13 contain a 12-nucleotide sequence of BKPyV ww agno gene 
(nucleotides number 4-15) immediately after the NCCR and the start codon of EGFP 
(Fig. 1A). We deleted the 12-nucleotide sequence in pRG13 (BKPyV-Dunlop) (Fig. 
1B) and phRG (BKPyV-Dunlop) and transfected HEK293 cells. Two days post-
transfection, we quantified the EVGR and LVGR expression by flow cytometry and 
calculated the mean fluorescence intensity (MFI) of EVGR (red) and LVGR (green) 
expression (Material and Methods in section 5.2). Surprisingly, both reporter 
vectors showed reduction in EVGR expression in favor of LVGR expression of more 
than 5-fold compared to the respective undeleted ones (Fig. 1C, D). We suspected 
the 12-nucleotide sequence harbored vital regulatory TFBS. To visualize this, we 
used the MatInspector tool (324) to search the 12-nucleotide sequence for the 
presence of TFBS. We identified putative TFBS including one for nuclear factor 1 
(NF1), which we called NF1-7 representing the 7th NF1 binding site with respect to 
the six NF1 bindings sites in the BKPyV ww NCCR (Fig. 2A). Since many studies 
have reported NF1 to be an important regulator of viral expression (325, 326), we 
made phRG (BKPyV-DUN) constructs with mutations within the 12-nucleotides 
sequence that would affect the core binding site of NF1 (NF1-7_mut1, NF1-7_mut2 
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and NF1-7_mut4) and another that would not affect the core NF1 binding site (NF1-
7_mut3) (Fig. 2A). The core NF1 binding site is shown on the right of Fig. 3A. The 
result revealed, that mutagenesis of the predicted NF1-7 site decreased EVGR 
expression to ~30%, while the LVGR expression increased ~2.6-fold, but not up to 
the levels of the deletion mutant (Fig. 2B, C). This indicates that other factors within 
the deletion may be involved in the regulation of EVGR and LVGR expression. On 
the other hand, mutation, which did not affect NF1 binding, had little or no effect on 
EVGR or LVGR expression. This result suggested that the immediate BKPyV agno 
coding sequence (nucleotides 4-15) contained an NF1 binding site, which may 
cooperate with other factors to regulate EVGR and LVGR expression of BKPyV. 
Since the 12-nucleotide sequence could have a regulatory function and novel HPyVs 
do not encode agno, we analyzed the HPyVs-NCCR activity in a bi-directional 
reporter pRG13D12 (D12 indicates pRG13 lacking the 12-nucleotide sequence) in 
section 5.2. 
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Fig. 1: (A) The bi-directional reporter vector pRG13 containing the BKPyV Dunlop 
NCCR (grey colored) in the early to late orientation, which was cloned via restriction 
sites MluI and BssHII; red fluorescence protein, dsRed2 as a marker of EVGR 
expression; green fluorescence protein, EGFP in opposite orientation, as a marker of 
LVGR expression; SV40 polyadenylation signals (SV40 polyA) in opposite 
orientations to stabilize the dsRed2 and EGFP messages; Colicin E1 ori for 
replication of the plasmid in bacteria; ampicillin resistant gene (Amp) for selection in 
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bacteria. The sequence below the map shows part of the NCCR, LVGR start codon, 
the 12-nucleotide sequence of BKPyV ww agno (underlined), BssHII restriction site 
and part of the EGFP sequence. This reporter contains the 12-nucleotide sequence 
of BKPyV agno located adjacent to the LVGR start codon (underlined). (B) The 
bidirectional reporter pRG13D12 is similar to the pRG13 except the deletion of the 
12-nucleotide sequence of agno. (C) Analysis of flow cytometry data of BKPyV ww 
and dunlop NCCRs cloned in pRG13 and pRG13D12 reporter vectors and 
transfected in HEK293 cells. Summary plot, red bars, sum of red cells (Q1+Q2); green 
bars, sum of green cells (Q2+Q4); yellow bars double-positive cells (Q2), where Q 
stands for the quadrants of the flows. (D) Normalized mean fluorescence intensity 
(MFI). The weighted MFI was calculated for each measurement (see formulas in 
Materials and Methods), late expression was normalized to BKPyVww NCCR (green 
MFI set as 100) while early expression normalized to BKPyVww NCCR (red MFI set 
as 1). Results shown are from 3 independent replicates. 
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Fig. 2: (A) The 12-nucleotide sequence (shaded blue, indicating nf1 binding) of 
BKPyV ww agno in the phRG reporter, adjacent is the BssHII site (shaded orange). 
The bases in red color within the 12-nucleotide sequence are the different mutation 
substituted within the core NF1 binding sites which can potentially affect nf1 binding 
(nf1-7_mut1, _mut2, and _ mut4) or in the non-core binding sites which may not 
affect nf1 binding (nf1-7_mut 3). The alphabets depict the single amino acid codes. 
On the right of Fig2A is the sequence logo of NF1 core binding site shown in capital 
letters. (B) Analysis of flow cytometry of BKPyV Dunlop NCCR cloned in phRGD12 
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reporter vector (12-nucleotide sequence deleted as explained above) and also 
cloned in phRG reporter vector including nf1 NCCR mutants. Transfection was done 
in HEK293 cells. x-axis, EGFP fluorescence, y-axis, dsRed2 fluorescence, 10,000 
mock transfected cells were gated for the live gate while 5,000 transfected cells were 
gated for the P3 (Q1, Q2 and Q4) gate. Q1, Q4 and Q2 depict cells expressing red, 
green and both, respectively. Ex. excitation wavelength, Em, emission wavelength. 
(C) Summary plot, red bars, sum of red cells (Q1+Q2); green bars, sum of green cells 
(Q2+Q4); yellow bars double-positive cells (Q2). (D) Plot of weighted MFI was 
calculated for each measurement (see formulas in Materials and Methods). 
 
 
This manuscript is under review. 
5.2 Novel human polyomavirus non-coding control regions differ in bi-
directional gene expression according to host cell, large T antigen 
expression and clinically occurring rearrangements 
There is a rapidly expanding family of HPyVs with 13 HPyVs identified so far, 
suggesting many more would be identified. The question of HPyVs’ host cell tropism, 
replication in cell cultures, route of transmission and associated diseases is raised. 
HPyVs widely infect humans and show differences in their associated diseases and 
tissue tropisms. Many aspects of the basic biology of these viruses, especially those 
of the novel HPyVs, are unknown. Presently, cell lines for propagating the novel 
HPyVs are lacking, thus hindering basic research on these emerging viruses. 
Currently, only BKPyV and JCPyV can be efficiently propagated in cell culture (305, 
306). Attempts to efficiently propagate MCPyV in cell culture were futile, as only low-
level virion production by transfection/infection of HEK293 cells was achieved with no 
serial transmission (17). To understand the primary host cell tropism, many studies 
have looked at the entry mechanisms of HPyVs into host cells by using VLPs, Vp1 
pentamers and pseudoviruses (327). The NCCR activity which can be used as an 
indicator of HPyV secondary host cell tropism and replication in cell culture, has not 
been thoroughly investigated, especially for the recently discovered HPyVs. The 
fundamental feature of the genome organization is similar among the family of 
HPyVs. However, the NCCR sequences differ among HPyVs with respect to lengt, 
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LTag-binding sites and TFBS, which may have influence on host cell tropism and 
viral replication. We hypothesized that the HPyVs will demonstrate different activity in 
cells derived from the same or different tissues. We designed a smaller bi-directional 
reporter vector based on the one described in Gosert et al., (25). The bi-directional 
reporter vector contains the red fluorescence protein (dsRed2), which serves as a 
marker of EVGR, and the green fluorescence protein (EGFP) as a marker of LVGR 
expression. We tested the NCCR activity of the 13 HPyVs including (rr)-NCCRs from 
HPyV7 and HPyV9 from patients and MCPyV point mutant from MCC using HEK293 
as our basic cell line. The early viral proteins (sTag and LTag) are involved in the 
regulation of EVGR and LVGR expression and viral genome replication. To 
characterize the effect of Tags on EVGR and LVGR expression, we analyzed our 
HPyV-NCCR reporter constructs in HEK293T cells constitutively expressing SV40 
Tags and HEK293MCT constitutively expressing MCPyV Tags. Next, to get an 
indication of secondary host cell tropism, we investigated the NCCR activity of the 13 
HPyVs in different cell lines originating from kidney, skin, lung, cervix, brain and 
colon. Quantification of EVGR and LVGR expression was performed by fluorescence 
microscopy and flow cytometry. 
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The data demonstrated that the NCCR of HPyVs is different in length, number and 
position of LTag and TFBS composition, which drive the differential bi-directional 
expression. This disparity in the NCCRs-driven expression in different cell lines is 
also due to the transcription factors (TFs) make-up in the cell lines. Some HPyVs 
presented with high EVGR or LVGR expression in cell lines derived from tissues, 
where they were reported to have tropism for or detected in. For instance, BKPyV 
and JCPyV known to have tropism for kidney and brain had highest EVGR in the 
kidney derived cells HEK293 or the brain derived cells HS683, respectively. MCPyV, 
suspected to have tropism for the skin, displayed its highest EVGR expression in the 
skin-derived A375 cells. While HPyV12 discovered from the liver of a colon 
carcinoma patient revealed a higher EVGR expression in the colon derived SW480 
cells. However, others showed high activity in cell lines derived from tissues where 
they have not so far been detected. This indicates that these HPyVs could have 
tropism for the body compartments where the cell lines were derived from or may be 
replicated in, however, this remains to be tested. BKPyV, JCPyV and MCPyV have 
been efficiently replicated in cell lines expressing SV40 or MCPyV Tags, respectively 
(305). SV40 Tags activated EVGR expression of HPyVs and MCPyV cognate Tags 
activated EVGR expression from the MCPyV NCCRs, indicating cell lines expressing 
cognate Tags of respective HPyVs could be used for their propagation. Analyses of 
rearranged NCCR variants for BKPyV and JCPyV have been greatly investigated (25, 
26). We reported that rearranged NCCR variants of novel HPyVs (HPyV7 and HPyV9) 
derived from patients increased EVGR as reported for BKPyV and JCPyV (25, 26) 
reiterating the NCCR as the pathogenicity determinant. Interestingly, even the 
rearranged NCCR variants of novel HPyVs demonstrated varied activity in different 
cell lines, indicating the host cell TFs make-up are also involved in the NCCR-driven 
viral expression. Our data are important for identifying host and viral factors 
necessary for culturing HPyVs and prediction of HPyVs secondary host cell tropism. 
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This work was performed together with Christian Baumann. 
5.3 Point mutations in the large T antigen binding sites of BK polyomavirus 
non-coding control region affect gene expression  
 
ABSTRACT  
 
The non-coding control region of all human polyomaviruses contain the origin of viral 
replication, which is made up of binding motifs for large T antigen (LTag). LTag 
interacts with these motifs to mediate viral genome replication and activation of late 
viral gene region (LVGR) expression as already described for the SV40. Since the 
LTag binding motifs between SV40 and BK polyomavirus (BKPyV) at the ori are the 
same, we hypothesised that the effect of LTag-binding sites mutageneses in BKPyV 
NCCR would be similar to that of SV40. We compared the EVGR and LVGR 
expression of BKPyV archetype (ww) NCCR defective in one or more LTag binding 
sites using a bidirectional reporter vector in HEK293 cell lines expressing no, small or 
large amounts of SV40 LTag. Our results demonstrated an increase in early viral 
gene region (EVGR) expression in all mutants in both HEK293T and HEK293TT cells 
compared to HEK293 cells. The EVGR expression increase was less in HEK293TT 
cells compared to HEK293T cells, however, mutants containing mutant A showed a 
lesser decrease of EVGR expression in HEK293TT cells compared to all other 
mutants without mutant A. Furthermore, mutants harboring mutant A displayed 
higher levels of EVGR expression compared to other mutants in both HEK293T and 
HEK293TT cells. Conversely, LVGR expression increase proportionally in HEK293T 
and HEK293TT cells; respectively. Nonetheless, mutants harboring A and D 
mutations, abrogated the further increase of LVGR in HEK293TT cells. 
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INTRODUCTION 
 
Polyomaviruses (PyVs) belong to the family Polyomavirdae, they are double-
stranded DNA (dsDNA) viruses with small circular genomes of approximately 5 kb 
(328). The genome is encapsidated in an icosahedral capsid of approximately 45 nm 
(1). The genome of PyVs is divided into 3 main regions: The early viral gene region 
(EVGR), late viral gene region (LVGR) and the non-coding control region (NCCR) 
(329). The EVGR encodes small and large T antigens (sTag and LTag), while the 
LVGR encodes viral structural proteins. The LTag possesses multifunctional roles, 
such as initiation and maintenance of viral genome replication, regulation of EVGR 
and LVGR expression, and assembly of virions (59, 330-332). Additionally, LTag 
leads to transformation by interacting with tumour suppressor proteins such as 
retinoblastoma proteins (pRB) and p53 (333).  PyVs’ sTag has been reported to be 
implicated in the transformation role of LTag (18, 260, 264). The NCCR of HPyVs of 
approximate 400-600 base pairs (bp) in length is located between the EVGR and the 
LVGR. The NCCR harbours LTag binding motifs mostly at the origin of viral 
replication (ori), a numerous transcription factor binding sites (TFBSs), enhancers, 
EVGR and LVGR promoters, which initiate and regulate the bidirectional expression 
of PyVs. The NCCR of BK polyomavirus (BKPyV) is approximately 400 bp. The 
archetype (ww) BKPyV NCCR is made up of linear sequence blocks arbitrarily 
denoted as O146 (containing the ori), P68, Q39, R63, and S63 (subscript numbers 
represent number of nucleotides). Two kinds of BKPyV NCCR architectures have 
been identified, ww- and rearranged (rr-) NCCRs. The rr-NCCRs consist of sequence 
deletions, duplications, or combinations of both. The rearrangement frequently 
occurs in the LVGR promoter side, while the EVGR promoter side containing the ori 
remain intact (22). The rr-NCCRs of BKPyV and JCPyV variants from patients 
suffering from BKPyV-associated nephropathy (BKPyVAN) and progressive 
multifocal leukoencephalopathy (PML), have been demonstrated to be associated 
with increased EVGR expression and viral replication (25, 26). The ori of PyVs is 
located in the NCCR, proximal to the EVGR side (49). The role of each LTag binding 
sites within the ori of HPyVs have not been well characterized, unlike in the monkey 
polyomavirus SV40 (59). The SV40 ori is consist of pentanucleotide sequences (5’-
GRGGC-3’ or 5’-GCCYC-3’), which are found at the oris. LTag interacts with these 
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pentanucleotide sequences via the origin-binding domain (OBD). This OBD is about 
50% identical among HPyVs and can activate transcription (334). Furthermore, this 
protein melts and unwind the dsDNA in an ATP-dependent manner. Additionally, 
other host’s factors such as topoisomerase I, polymerase alpha primase complex 
and replication factor A are recruited by LTag to the site of replication initiation (335, 
336). Additional functional domain of the LTag, such as the DnaJ domain plays a vital 
role in viral genome replication in vivo (337), however, dispensable for viral 
replication in vitro (338). The SV40 ori is made up of two LTag binding motifs 
proximal to the EVGR with the ori referred to as site I, and four centrally located LTag 
binding sites referred to as site II (59). The SV40 minimal ori is characterised by 
three sequence motifs that is, a centrally located four-pentanucleotide repeats (site II), 
a poorly conserved early palindrome (EP) sequence proximal to the early side of the 
ori, and a conserved AT-rich sequence near the late side of the ori (49). The SV40 ori 
is made of 2 LTag binding motifs on the early side of the ori called site I, and four 
centrally located LTag binding sites called site II within the ori (49). A similar ori 
organization is found in BKPyV ww, JCPyV ww, Merkel cell polyomavirus, human 
polyomavirus 9, human polyomavirus 12 (49). As reported for SV40, each base pair 
of the pentanucleotide sequence is critical for LTag binding and viral replication (59). 
However, adjacent sequences to these LTag binding sites have little or no influence 
on the binding of LTag and viral replication (59). This suggests that the 
pentanucleotide sequence at the viral ori is the fundamental functional unit for LTag 
binding and viral DNA replication (339). Adjacent LTag binding sites increase the 
stability of LTag binding. In SV40, the main function of LTag binding to site I is the 
auto-regulation of EVGR expression (59). LTag binds to site I and represses the 
transcription of EVGR, whereas the function of site II is to bind and position LTag in 
the correct orientation and location for its function in viral genome replication (59). 
The 6 LTag binding sides near the EVGR side of BKPyV ww are similarly organized 
compared to the 6 LTag binding sites of SV40 (49). The roles of the SV40 LTag 
motifs in the regulation of the SV40 bidirectional expression have been well 
described (59), however, very little is known about that of BKPyV. The LTag binding 
motifs between SV40, BKPyV and JCPyV at the ori are the same, we hypothesize 
that the role of the LTag binding motifs in BKPyV is similar to that of SV40 (49). In 
order to elucidate the role of BKPyV LTag-binding motif, we compared in a 
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bidirectional reporter vector the EVGR and LVGR expression of BKPyV ww NCCR 
with those of BKPyV ww NCCR defective in one or more LTag-binding motif in 
HEK293 cells expressing none, a small or large amounts of SV40 LTag. Our results 
showed the mutants containing mutant A displayed a lesser decrease in HEK293TT 
cells compared to other mutants. While the LVGR expression proportional increase is 
abrogated for mutants harboring mutants, A and D. 
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RESULTS 
LTag mutagenesis and mutant naming 
 
We identified by MatInspector software seven LTag binding sites (Fig. 1). Six of 
these sites are contained in the ori and are similarly organized compared to the six 
LTag binding sites of SV40 (49). We performed different mutageneses within the 
LTag-binding sites in the BKPyV ww NCCR by substituting the first two bases of the 
sites as follows; (G->T, C->A or vice versa), and the mutant NCCRs were reanalyzed 
by MatInspector for LTag binding, while allowing 2 mismatches. In silico analyses 
indicated no LTag binding after introducing two substitutions. To ease naming of the 
mutants, we assigned the DNA strand that goes in 5’ to 3’ direction from the EVGR 
via the NCCR to the LVGR as the forward strand. Likewise, we named the strand 
that goes in 5’ to 3’ direction from the LVGR through the NCCR to the EVGR as the 
reverse strand. Two sites were identified on the forward strand (pink) (5’-GRGGC-3’) 
and five on the reverse strand (yellow) (5’-GCCYC-3’) (Fig. 1). The BKPyV contains 6 
LTag binding sites within the ori (49). Two LTag binding sites referred to as site A 
proximal to the EVGR (site I in the SV40 nomenclature) and four centrally located 
motifs are found adjacent to an AT-rich sequence referred to as site B and C (site II 
in the SV40 nomenclature) (49). These 4 sites contained two forward motifs referred 
to as site B and two reverse motifs referred to as site C in the BKPyV nomenclature. 
The B and C sites are each separated by one nucleotide as shown for SV40 (49). 
Finally, the LTag binding site outside the ori, referred to as site D, is proximal to the 
LVGR side (Fig.1). All the other LTag binding sites on the reverse strand contain a 
thymine at the fourth position of the reversed motifs 5`GCCYC`3 except LTag binding 
site D, which contains a cysteine instead of a thymine at this position. LTag binding 
sites in close proximity and on the same strand were mutated together. This provided 
a total of four possible LTag binding site mutants, which were labelled A (R1 and R2), 
B (F1 and F2), C (R3 and R4) and D (R5), where ‘R’ stands for reverse and ‘F’ for 
forward, while the numbers are the motifs numbering from EVGR to the LVGR (Table 
S1). D site was the only single site mutated alone (Table S1). Altogether, eight 
different mutants including combination of the different LTag binding site mutants 
were made (Table S1). The LTag binding mutagenesis affected some TFBS within 
the NCCR. However, apart from binding sites for E2F4 and Sp1 (highlighted in yellow) 
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affected due to D mutation, most of the TFBS affected are not found in the kidney 
(Table S2).  
 
Effect of LTag binding site mutants on EVGR and LVGR expression in HEK293 
cells 
To examine the effect of the different NCCRs defective of LTag binding, we cloned 
them in the bidirectional reporter vector pRG13D12, transfected HEK293 cells and 
measured the EVGR and LVGR expression by flow cytometry. Mutation of B, C and 
D sites showed a gain of function for EVGR expression in HEK293 cells, while all 
other mutant combination containing A site mutation presented with a loss of function 
for EVGR expression compared to the un-mutated archetype. Conversely, mutant 
combinations containing mutation in A or D site alone, revealed a loss of function for 
LVGR expression compared to the archetype. Whereas, the LVGR expression of 
mutants, B and C sites showed little or no effect. 
 
Effect of LTag binding site mutants on EVGR and LVGR expression in HEK293-
derivative cell lines that constitutively expressing SV40 LTag in different 
amounts  
To measure the effect of the different LTag binding site mutants in the presence of 
small and large amounts of LTag, we transfected HEK293, HEK293T and HEK293TT 
cells constitutively expressing none, a small or large quantity of LTag (Fig. 3). Two 
days post transfection we analyzed the EVGR and LVGR expression by flow 
cytometry as previously described (34). Furthermore, we calculated the EVGR MFI of 
each construct normalized to their corresponding EVGR MFI in HEK293 cells set as 
1. Our result depicted 3 distinct groups based on EVGR expression patterns (Fig. 3A). 
We could identify group wwE (mutants with similar EVGR expression pattern as 
archetype), group A (all mutants harboring mutation A) and group D. Compared to 
the corresponding expression in HEK293 cells, all groups exhibited a gain of function 
for EVGR expression in HEK293T cells. The EVGR expression in HEK293TT cells in 
the 3 groups were as follows; for group wwE the EVGR expression was reduced to 
the levels in HEK293 cells, while for group A it remained at similar levels to the 
corresponding levels in HEK293T cells and lastly, for group D the level was reduced 
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below the corresponding expression in HEK293 cells (Fig.4A). In addition, mutants 
containing A site mutation generally showed higher EVGR expression fold in both cell 
lines expressing LTag compared to other mutants (Fig. 4A). Mutations in A site 
presented with very slight decrease of EVGR in HEK293TT cells compared to other 
mutantions (Fig.4A). This implies that abolishing LTag interaction to the site A by 
mutagenesis prevents the EVGR expression decrease in HEK293TT cells as seen 
for other mutants in combination with A site mutant. 
We also calculated the LVGR MFI of each construct normalized to their 
corresponding LVGR MFI in HEK293 cells set as 1. With respect to the LVGR, we 
were able to identify 2 different groups regarding LVGR expression patterns, in 
particular group wwL (mutants with similar LVGR expression pattern as archetype) 
and group AD (all mutants harboring both mutation A and D). Compared to 
corresponding expression in HEK293 cells both groups revealed a gain of function 
for LVGR expression in HEK293T and HEK293TT cells. However, all except mutants 
containing A and D mutations displayed a proportional LVGR expression 
corresponding to increasing amounts of LTag (Fig. 4B). This indicates that mutation 
in both A and D sites together abrogated further LVGR activation in HEK293TT cells. 
Interestingly, mutants with either A or D alone still permitted the LVGR activation in 
HEK293TT cells (Fig. 4B), thus indicating a cooperative action of LTag interaction to 
both sites to increase LVGR expression in the presence of high amounts of LTag 
expression.  
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DISCUSSION 
 
Here we report that reduced-EVGR expression in the presence of large amounts of 
LTag expression can be via LTag binding site A, LVGR expression increase can be 
via both sites A and D. The oris of the 13 HPyVs has been reported (49). The 
number, orientation and spacing of LTag binding motifs at the ori of SV40, BKPyV 
and JCPyV are the same (49). SV40 and BKPyV core oris contain 4 centrally 
identical LTag binding motifs termed site II with respect to SV40 and site B, C with 
respect to BKPyV nomenclature (49). The two other motifs located proximally to the 
EVGR termed site I with regard to SV40 and site A with respect to BKPyV 
nomenclature are separated by 7 A-rich bps. BKPyV has a 7th LTag binding motif 
termed D motif located proximal to the LVGR side (Fig.1). Other HPyVs such as, 
MCPyV, HPyV10 and STLPyV also encode LTag binding motifs outside their oris, 
proximal to the LVGR side (Fig. 1 section 5.1). However, the role of these sites is yet 
to be elucidated. 
Since the roles of the SV40 LTag motifs with respect to regulation of EVGR and 
LVGR and viral genome replication are well known and the motifs between SV40, 
BKPyV and JCPyV at the ori are the same, we hypothesize that mutageneses of 
BKPyV`s LTag-binding sites will show similar effect compared to SV40. We analyzed 
EVGR and LVGR expression of BKPyV ww NCCR defective in one or more LTag-
binding sites compared to BKPyV ww-NCCR in HEK293 cells expressing none, a 
small or large amount of SV40 LTag.  
To get an indication of the effect of the LTag mutants in the absence of LTag, we 
analyzed the EVGR and LVGR expression in HEK293 cells. All mutations harboring 
site A mutagenesis displayed a loss of function for EVGR, while mutants B, C, and D 
showed a gain of function for EVGR expression compared to BKPyV ww-NCCR (Fig. 
2A), suggesting that mutagenesis of site A may results in a loss of activating 
transcription factor binding sites (TFBS) or gain of repressing TFBS (Table S2). 
However, the reverse could be plausible for the other mutants. On the other hand, 
mutants A, D and mutants harbouring A site mutantion exhibited a loss of function for 
LVGR expression, whereas mutant B and C has little or no effect, indicating a loss of 
activating TFBS once the A and D sites were mutated. Specifically, mutation in the D 
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site showed an in-silico loss of Sp1 and E2F4 binding, which were the only affected 
factors found in the kidney (Table S2). This is in line with the published work of 
Bethge et al., whereby Sp1-4 core site mutagenesis led to an increase in EVGR in 
expense of LVGR expression (340). However, our results were not exactly the same 
compared to that of Bethge et al, which could be due to the fact that the D site 
mutation did not affect the Sp1-4 core binding site, suggesting Sp1 may still be 
interacting with the binding site in a reduced affinity. 
Next, we investigated the effect of these NCCR-mutants defective in LTag binding in 
HEK293 cells producing small and large amounts of SV40 LTag, HEK293T and 
HEK293TT cells, respectively. Interestingly, all mutants including mutant combination 
where all LTag-binding sites were disrupted, showed higher EVGR expression in 
HEK293T cells compared to HEK293 cells. Moreover, the EVGR expression pattern 
between the different mutants were regulated differently in HEK293T and HEK293TT 
cells, resulting in the depiction of 3 different groups that is groups, wwE, A and D (Fig. 
3A). Group A (mutants harbouring mutant A) generally shows higher EVGR 
expression in both HEK293T and HEK293T cells compared to other mutants, 
indicating that mutation of binding site A leads to gain of function for EVGR 
expression in the context of LTag expression as previously reported for SV40 with 
site I mutation (341). Intriguingly, all mutants including the mutant where all the LTag 
binding motifs were mutated (ABCD) presented with elevated levels of EVGR 
expression in HEK293T cell. Further studies are required to examine this elevation, 
which most probably do not involve LTag interaction to its binding sites, however, 
may reflect LTag inhibition of EVGR-negative regulatory factors or increase in 
plasmid copy numbers. However, our preliminary copy number quantification does 
not correlate with the EVGR expression (Fig. 4C). 
Furthermore, we showed that EVGR expression of mutants in group wwE and D 
increased in HEK239T cells expressing small amounts of LTag and greatly 
decreased in HEK293TT cells expressing large amounts of LTag compared to 
mutants containing A mutation (group A). In summary, mutating the LTag-binding site 
A or combination of LTag-binding site A with other LTag-binding sites (group A) 
abrogated the EVGR-expression decrease, indicating a specific role of LTag-binding 
sites with respect to EVGR expression.  
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In addition, except mutants containing both A and D mutation (group AD) there was a 
proportionate increase in LVGR expression in the presence of increasing amounts of 
LTag expression, which was similarly described for JCPyV LVGR activation by SV40 
LTag (342). This suggests that the proportionate increase of LVGR expression can 
be mediated via sites A and D, since mutants containing either A or D or other LTag 
binding sites still show this proportional increase in LVGR expression. Taken 
together, while LTag-binding site A can be involved in the decrease of EVGR 
expression in abundant LTag expression, LVGR expression can be increased by 
cooperative involvement of LTag-binding sites A and D. Interestingly, like the EVGR 
expression of all mutants including mutant ABCD displayed elevated levels of LVGR 
expression in HEK293T cells. However, the mechanism cannot be deciphered with 
this current study. However, LTag inhibition of negative LVGR regulatory factors or 
copy number effect can be suspected. A summary model of the results is depicted in 
Fig. 5. 
Lastly, site II in SV40 is reported to play a role in SV40 replication, but not expression 
(59). Mutation of a corresponding site in BKPyV, sites B and C, showed little or no 
effect with respect to EVGR and LVGR expression in the context of LTag expression 
compared to the archetype, thus corroborating the SV40 results (59). Our current 
study cannot explain viral replication, Nonetheless, our preliminary copy number 
quantification does not correlate with the expression, indicating copy numbers might 
not play a role in the expression pattern depicted. 
In this study, we analyzed the effect of SV40 LTag on the BKPyV ww-NCCR 
defective of LTag binding motifs. However, one cannot exclude that the BKPyV 
cognate LTag might give different results. Nonetheless, the SV40 and BKPyV LTag 
have great similarity, and the fact that BKPyV can replicate in Cos-7 cells 
constitutively expressing SV40 LTag argue against this possibility. Here, EVGR and 
LVGR expression were analyzed using the bidirectional reporter vector. Further 
experiments are required to quantify the viral replication potential of the various 
NCCR mutant defective of LTag binding motif by cloning in a Dunlop backbone and 
perform viral replication studies in cell culture. However, the fact that BKPyV and 
SV40 have similar LTag binding sites and show similar EVGR and LVGR expression 
regulatory mechanism via the LTag binding sites, suggests that results obtained from 
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studying BKPyV can be extrapolated to other HPyVs such as, JCPyV with similar 
LTag binding site organization. 
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MATERIALS AND METHODS 
Plasmids 
We used the bidirectional reporter vector designed a new-smaller bi-directional 
reporter pRG13D12 described, similar to the phRG reporter described in Gosert et al 
(25). The reporter lacks the SV40 early promoter, beta globulin poly-adenylation 
signals, Hygromycin gene present in the NCCR cloned in phRG (25). PUC57 vector 
containing HPyV NCCR without the 12-nucleotide sequence. NCCRs defective of 
LTag binding were purchased from Eurogentec (Eurogentec S.A, Belgium). The 
NCCRs were excised from the pUC57 vector by using the restriction enzymes BssHII 
and MluI (New England Biolabs, England). The NCCRs were cloned via the 
corresponding restriction sites in the bi-directional vector, pRG13D12. Constructs 
with the right NCCR were verified by the 3130 Genetic Analyzer Sanger sequencer 
(Applied Biosystems, Switzerland). 
Cell lines 
 
The following cell lines, HEK293 cells (CRL1573, ATCC, Manassas, VA, USA), 
HEK293T cells (CRL3216, ATCC, Manassas, VA, USA), HEK293TT cells (0508000, 
NCI-Frederick Repository Service, Frederick, Maryland, USA), were grown in 
Dulbecco’s modified Eagle’s medium with high glucose (DMEM-H, D5671, Sigma-
Aldrich, St. Louis, MO, USA) containing 10% FBS (S0113, Biochrome AG, Berlin, 
Germany) and 2mM L-glutamine (K0302, Biochrome AG, Berlin, Germany). The 
medium of HEK293TT cells was supplemented with 400µg/mL hygromycin B 
(Calbiochem, San Diego, CA, USA). The cells were cultured in a HERA cell-150 
incubator (Thermo Fischer Scientific, Switzerland) at a temperature of 37°C and 5% 
CO2.  
 
Western blot 
 
HEK293, HEK293T, and HEK293TT cells were lysed in triple-buffer (50 mM Tris-HCl 
[pH 8.0], 150 mM NaCl, 1% NaDOC, 1% Triton X-100 and 0.1% SDS) containing 1x 
protease inhibitors. Equal volume of 10μg of cell lysates were separated by SDS-
PAGE using running buffer (50 mM Tris base, 199mM Glycine, 0.1% SDS, pH 8.3) at 
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25mA for 50 mins. The proteins were then electro-transferred (semi dry method) onto 
0.45 μm polyvinylidene difluoride (PVDF) membrane (IPFL00010; Millipore/Merck, 
Darmstadt, Germany) using 1x transfer buffer (10x: 48mM Tris base, 390m M 
Glycine, 10% SDS) at 70mA for 48 minutes. The membrane was dried, reactivated 
with 5 mL methanol (Sigma-ALDRICH, Switzerland) and washed with milli-Q H2O. 
Odyssey blocking buffer (927-40000; Licor, Lincoln, NE, USA) diluted 1:2 in Tris-
buffered saline (TBS) was used to block the membrane at RT for 1 h. Incubation of 
the membrane was done in the following primary antibodies: monoclonal mouse anti-
actin (1:5’000; Abcam, Cambridge, England), polyclonal rabbit anti-LTag (1:10’000; 
Professor Christine Hanssen Rinaldo, University of North Norway in Tromsö, 
Norway), diluted in 1:2 Odyssey blocking buffer-TBS-0.1% Tween20 at 4oC overnight. 
The membrane was then washed at least 5x with TBS-0.1% Tween 20. Next, the 
membrane was incubated in the following secondary antibodies: donkey anti mouse 
Alexa Fluor 680 (1:15000; A10038; goat anti-rabbit antibody-IRDye 800CW (1:10,000; 
926-32211; Licor), invitrogen) diluted in 1:2 Odyssey blocking buffer TBS, 0.1% 
Tween20 at RT for 1hr. The membrane was washed at least 3x with TBS-0.1% 
Tween20. Detection and quantification of protein was done with the Licor Odyssey 
CLx instrument (Licor, Homburg, Germany). 
 
Transfection 
 
All cell lines were transfected with 3µL Lipofectamine 2000 (1734997, Invitrogen, 
Carlsbad, CA, USA) and 1µg plasmid DNA construct in a 12 well plate, according to 
manufacturer’s instructions. Prior to transfection the cells’ confluency ranged 
between 70-90%. 24 hrs post-transfection, medium was replaced with DMEM-H/10% 
FBS complemented with 2mM Glutamine. 48 hrs post-transfection, fluorescence 
images were taken by fluorescent microscopy and EVGR (RFP) and LVGR (GFP) 
expression quantified by flow cytometry. 
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Flow cytometer-based quantification 
 
Forty-eight-hour post-transfection cells were washed once with 1mL PBS/2.5 mM 
EDTA (BioConcept, Switzerland) and then trypsinized with trypsin (without phenol 
red) /0.25mg/mL EDTA (Lonza, MD, USA). The cells were suspended in 1ml DMEM 
(without phenol red) containing 20mM of HEPES, 2mM Glutamine, 1% FCS and 1% 
Penicillin/Streptomycin (P/S) (Thermo Fischer Scientific, Switzerland) and transferred 
to 5 ml polystyrene round-bottom tubes (BD, Franklin Lakes, NJ, USA). Prior to each 
measurement, DAPI (D8417, Sigma-Aldrich, St. Louis, MO, USA) was added as a 
dead-cell marker to a final concentration of 1 ng/ml.  Fortessa Cytometer (BD, 
Franklin Lakes, NJ, USA) was used for the flow cytometry measurements. RFP, 
Excitation was 561 nm (Yellow-Green Laser), Emission was 586/15 nm; GFP, Ex. 
488 nm (Blue Laser), Em. 530/30 nm and DAPI, Ex. 405 nm (Violet Laser), Em. 
450/50 nm. The weighted mean fluorescence intensities (MFI) for EVGR (red) and 
LVGR (green) expression were calculated by inserting the cell number (N), mean 
fluorescence (I) of the quadrants Q1 (red cells only), Q2 (red and green cells), and 
Q4 (green cells only) into the respective formulas: MFI red = ()*∗,)* -(()/∗,)/)(()*-()/-()1) ; MFI green = ()/∗,)/ - ()1∗,)1()*-()/-()1 . EVGR expression of all HPyV constructs was 
normalized to the EVGR of BKPyVww set as 1 while LVGR expression of all HPyV 
constructs was normalized to the LVGR of BKPyVww set as 1.  
 
Plasmid copy number quantification 
 
Plasmid copy numbers were quantified after total DNA extraction from cells 
suspended in 200ul PBS. A QIAamp DNA blood kit (Qiagen Hombrechtikon, 
Switzerland) was used for the extraction according to the manufactural instructions. 
Quantitative PCR protocol for detecting dsRed2, primers and probes shown below 
was used. 
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The following primer and probe was used for the qPCR 
 
 Sequence (5’ – 3’) Length/%GC Tm [°C] 
Primer    
 
DsRed2_f 
 
 
GGT GGA GTT CAA GTC CAT CTA CAT G 
25 bp/48 57.1 
DsRed2_r CCA CGA TGG TGT AGT CCT CGT T 22 bp/54.5 58.7 
Probe  
  
DsRed2_
FAM 
FAM- CGG CTA CTA CTA CGT GGA CGC 
CAA GCT-TAMRA 
27 bp/59.3 65.1 
    
 
Amplicon: 121bp 
 
Primers and probe concentrations used for qPCR 
 
2X 
Mastermix 
 
10 µM Per Reaction Per x10 Final Conc. nM 
qPCR Mix  12.50 µL 125.00 µL  
Forward 
Primer 
10 0.25 µL 2.50 µL 100 
Reverse 
Primer 
10 0.25 µL 2.50 µL 100 
Probe 10 0.25 µL 2.50 µL 100 
Template DNA 5.00 µL -  
Water  6.75 µL 67.50 µL  
Total 
volume 
 25 µL -  
 
 
In silico analysis of BKPyV ww NCCR 
 
The MatInspector software tool (Genomatix, Munich, Germany)(324) was used to 
search for l potential LTag binding sites within the BKPyV ww NCCR. For identifying 
potential LTag binding sites the BKPyVww NCCR was uploaded into the software 
and the user-defined IUPAC string using the LTag binding site consensus sequence, 
GRGGC (where R = A or G) allowing no mismatch.  
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Statistics 
 
The Mean and standard deviations were calculated from three independent 
transfections using GraphPad Prism software (version 6 for Mac OS).  
 
 
FIGURE LEGEND 
 
Fig. 1: Presentation of BKPyV ww NCCR with putative LTag binding sequence 
motifs.  The LTag binding motifs are numbered from left to right (1-5) according to 
their respective orientations. (R= reverse and F= forward), binding site A contains 2 
motifs (R1 and R2), site B (F1 and F2), site C (R3 and R4) and site D (R5). The 
number of the bp of each site is depicted. Lastly, the EVGR and LVGR start codon 
(ATG) are shown on the reverse and forward strands, respectively. 
 
Fig. 2:  Differential effect of LTag binding site mutants in HEK293 cells. (A) MFI 
of EVGR expression normalized to EVGR MFI BKPyVww set as 1. (B) MFI of LVGR 
expression normalized to EVGR MFI BKPyVww set as 1. NCCR driven EVGR and 
LVGR expression measured by FACS and MFI calculated as described in materials 
and methods. Error bars represent standard deviation of three independent 
experiments. 
 
Fig. 3: Western blot of LTag expression in HEK293, HEK293T and HEK293TT cell 
lines. 
 
Fig. 4: Downregulation of EVGR and upregulation of LVGR expression in 
abundant amounts of LTag. (A) EVGR expression fold in HEK293T and HEK293TT 
cells normalized to corresponding EVGR expression in HEK394 cells set as 1. Based 
on EVGR expression patterns, 3 groups were depicted (groups wwE, A and D). (B) 
LVGR expression fold in HEK293T and HEK293TT cells normalized to corresponding 
LVGR expression in HEK394 cells set as 1. Based on LVGR expression patterns, 2 
groups were depicted (groups wwE, AD). Error bars indicate standard deviation of 
three independent experiments. 
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Fig. 5: A model depicting the effect of LTag-binding sites mutageneses. (A) In 
HEK293 cells containing no LTag, host transcription factors (orange ovals) interact 
with the BKPyV ww NCCRs to maintain the bidirectional EVGR (red arrow) and 
LVGR (green arrow) expression balance. (B) In the presence of small amount of 
LTag in HEK293T cells (few yellow triangles), EVGR and LVGR expression is 
increased via an unknown mechanism, (LTag binding sites, A = inverted V in light 
blue, B and C = inverted V in thick blue and D = inverted U in pink), since the mutant 
with all LTag binding sites mutated, displayed higher levels of EVGR expression. 
This may reflect inhibition of EVGR and LVGR negative regulatory factors by LTag 
(pink oval in contact with yellow triangle). (C) In the presence of large amounts of 
LTag in HEK293TT cells, LVGR expression increase even more for all mutants 
except in mutants containing mutant A and D mutations. Indicating the addition 
increase is mediated via A and D sites. Whereas, EVGR expression decreases 
compared to the levels in HEK293T cells for all mutants except those harboring 
mutant A indicating that the reduced EVGR expression involves site A. B and C sites 
showed little or no influence of EVGR expression in HEK293 cells expressing LTag. 
The expression pattern is similar to that of the ww NCCR. These sites may be 
involved in viral replication as described for a homologous site II in SV40. 
 
Supplementary data 
Table S1: Binding sites that are mutated in each of the mutants. 
Table S2: TF binding sites that are gained or lost by mutations in LTag binding sides. 
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FIGURES 
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Fig. 2 
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Fig. 3 
 
 
 
 
 
 
Fig. 4 
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Fig. 5 
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Table S1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2 
 
 
 
 
 
 
  
Mutation TF 
Gain (+) / loss (-) 
of TF site in 
mutant 
TF detail Tissues in which TFs are found Core sim. 
Matrix 
sim. 
A 
 
CIZ - CAS interating zinc finger 
protein 
Skeleton 1 0.976 
NKX31 + NK3 homeobox 1 Cardiovascular System/ Central 
Nervous System/ Digestive System/ 
Embryonic Structures/Endocrine 
System/ Heart/ Islets of Langerhans/ 
Lung/ Muscles/ Myocardium/ 
Nervous System/ Pancreas/ 
Prostate/ Respiratory System/ Spinal 
Cord/ Thyroid Gland/ Urogenital 
System 
1 0.817 
RFX3 - Regulatory factor X 3 Antibody-Producing Cells/ Blood 
Cells/ Endocrine System/ Immune 
System/ Leukocytes/ Lymphocytes/ 
Testis/ Urogenital System 
1 0.762 
ZFX - X-linked zinc finger protein Embryonic Structures/ Endocrine 
System/ Germ Cells/ Ovary/ Testis/ 
Urogenital System 
1 0.971 
B 
 
KLF2 - Krueppel-like factor 2 
(lung) (LKLF) 
Blood Cells/ Bone Marrow Cells/ 
Embryonic Structures/ Erythrocytes/ 
Hematopoietic System 
1 0.986 
PURα - Purine-rich element binding 
protein A 
Brain/ Central Nervous System/ 
Muscle, Smooth/ Muscles/ Nervous 
System/ Neuroglia/ Neurons 
1 0.97 
ZNF65
2 
- Zinc finger protein 652   1 0.76 
C 
ZFX - X-linked zinc finger protein Embryonic Structures/ Endocrine 
System/ Germ Cells/ Ovary/ Testis/ 
Urogenital System 
1 0.974 
D 
 
ZBED4 - Zinc finger, BED-type  1 0.96 
E2F4 - E2F transcription factor 4 ubiquitous 1 0.975 
LRRFI
P1 
- Leucine rich repeat (in 
FLII) interacting protein 1 
 0.842 0.821 
GCM1 + Glial cells missing homolog 
1 
Embryonic Structures/ Endocrine 
System/ Immune System/ 
Parathyroid Glands/ Thymus Gland 
1 0.834 
INSM1 - Zinc finger protein 
insulinoma-associated 1 
(IA-1) functions as a 
transcriptional repressor 
Digestive System/ Endocrine 
System/ Liver/ Pancreas 
1 0.918 
KLF7 - Krueppel-like factor 7 Blood Cells/ Bone Marrow Cells/ 
Embryonic Structures/ Erythrocytes/ 
Hematopoietic System 
1 0.987 
MAZR - MYC-associated zinc finger 
protein 
Blood Cells/ Immune System/ 
Leukocytes 
1 0.898 
SP1 - Stimulating protein 1 ubiquitous 1 0.987 
ZBTB7 - Zinc finger and BTB 
domain containing 7A 
Blood Cells/ Immune System/ 
Leukocytes/ Lymphocytes/ Thymus 
Gland 
1 0.927 
	
Mutants Mutated binding sites 
A R1, R2 
B F1, F2 
C R3, R4 
D R5 
AC R1, R2, R3, R4 
ABC R1, R2, R3, R4, F1, F2 
ACD R1, R2, R3, R4, R5 
ABCD R1, R2, R3, R4, R5, F1, F2 
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Co-authored publications during the course of this PhD thesis. 
 
1. Tobias Bethge, Elvis T. Ajuh, Hans H. Hirsch* (2016) Imperfect Symmetry of 
Sp1 and Core Promoter Sequences Regulates Early and Late Viral Gene 
Expression of the Bi-Directional BK Polyomavirus Non-Coding Control Region 
J. Virol 90: 10101. 
Contribution: Performed transfection, western blot, contributed in writing the 
manuscript and approved the final copy. 
 
2. Donor-derived urothelial cancer after kidney transplantation associated with a 
BK polyomavirus with increased oncogenic potential  
Contribution: Carried out experiments in molecular characterizing the BKPyV 
from the urothelial cancer and contributed in writing the manuscript. 
 
5.4 Imperfect symmetry of Sp1 and core promoter elements regulates early 
and late  viral gene expression of the bi-directional BK polyomavirus non-
coding control region   
Specificity protein 1 (Sp1) has a crucial role in the transcription of both cellular and 
viral genes (343). All cells of the human body ubiquitously express this transcription 
factor (344). Sp1 binds to GC-box motifs found in SV40 and BKPyV NCCR and its 
binding is vital for the regulation of EVGR and LVGR expression (340). This GC-box 
motif is found on the NCCR of all HPyVs, suggesting a vital role for this sequence in 
the growing family of HPyVs. Our group reported a detailed point mutants of the 
BKPyVww NCCR defective in 28 different TFBS without changing the overall BKPyV 
ww-NCCR length and architecture. A hierarchy of TFBS was identified, whereby 3 
phenotypic groups were detected: group 1 TFBS mutations revealed activation of 
EVGR expression in expense of LVGR expression and strong replication rates 
similar to what was reported for BKPyV rr-NCCR variants from patients. Group 2 
TFBS mutants displayed an intermediate phenotype with regards to EVGR 
expression and replication capacity, while group 3 showed reduced EVGR and LVGR 
expression and allowed modest or no viral replication (340).  
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Among all the TFBS, Sp1 sites revealed a prominent role in BKPyV NCCR-driven 
expression. BKPyV NCCR has at least 3 Sp1 binding sites; two of these sites (Sp1-2 
and Sp1-4) appeared to have underlying opposite effects in the expression and 
replication of BKPyV. Mutagenesis of the Sp1-4 site proximal to the LVGR 
demonstrated a strong EVGR expression, whereas inactivation of Sp1-2 site 
proximal to the EVGR overrode both EVGR and LVGR expression. This effect of 
sp1-2 mutant was also recorded in group 1 mutants including sp1-4 mutant, 
indicating a vital regulatory role of SP1 in the NCCR as a whole (340). 
The role of these two Sp1 sites and their relationship to core promoter elements in 
the BKPyV ww-NCCR was examined in greater detail. This role of Sp1 sites in 
BKPyV could be extrapolated to other HPyVs, especially those with similar Sp1 sites 
and core promoter elements (CPEs) architecture. We examined the bi-directional 
balance of EVGR and LVGR expression and viral replication with respect to Sp1-2 
and Sp1-4 sites strand orientation, affinity and number of Sp1 sites. In addition, the 
contribution of EVGR and LVGR CPEs in EVGR and LVGR expression was also 
investigated 
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We demonstrated that the affinity, position and strand orientation of Sp1-2 and Sp1-4 
proximal to the EVGR and LVGR sites exerted different effects on BKPyVww NCCR-
driven EVGR and LVGR expression. Swapping the high-affinity Sp1-4 site and the 
low-affinity Sp1-2 site (e.g., NCCR 14r2r), lowering the Sp1-4 affinity by introducing 
affinity-lowering mutations (e.g., NCCR 12(4-5CG)), flipping the orientation of the 
Sp1 sites (e.g., NCCR 124r) and various combinations of permutations upset the 
EVGR and LVGR balance and led to a significant EVGR expression in most cases. A 
step-wise lowering-affinity mutations caused a decline in EVGR expression in the 
NCCR 14r4 containing the high-affinity Sp1-4 site in respective EVGR and LVGR 
proximal positions. Duplicating the lower-affinity Sp1-2 site increased EVGR 
expression and elevated viral replication compared to BKPyV ww, suggesting that 
two lower-affinity sites were better than one or none. The non-palindromic nature of 
Sp1 sites and alteration from the consensus organization affected the BKPyVww 
NCCR-driven EVGR-LVGR balance. 
There was evidence, that the Sp1 regulatory balance of EVGR and LVGR acted in 
conjunction with CPEs showing an imperfect symmetry of Sp1, EVGR and LVGR 
core promoters with TATA and TATA-like elements. The EVGR of BKPyVww NCCR 
fulfil the criteria of a regulatory promoter whereas LVGR promoter cannot be easily 
classified, but it is similar to a TATA-less housekeeping promoter described in 
Saccharomyces cerevisiae, which actually contains TATA-like elements. 
Most rr-NCCR variants from patients lacking the late promoter sequences maintained 
the late DPEs. Deletion of the LVGR promoter increased EVGR expression at the 
expense of LVGR expression. However, progeny production relied on LVGR gene 
products. Transfection experiments of Sp1-4 and TATA-like elements deletion in the 
LVGR promoter in cell lines expressing different amounts of SV40 LTag showed, that 
LTag can overcome the effect of the deletions by increasing LVGR expression. The 
results corroborate previous studies showing that SV40 LTag was able to rescue a 
non-functional promoter lost due to lack of TBP-associated factor (TAF). Since TAFs 
and TBP have been shown to form the TFIID complex and bind the core promoter 
elements (DPEs, Inr, and TATA elements), LTag may activate LVGR promoter by 
exerting a TAF-like function with TFIID complex to recognize the remaining CPEs, 
the DPEs and the dispersed Inr. 
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The dissection of these different point mutations in BKPyV ww NCCR may also have 
implications for other HPyVs, especially those with similar NCCR architecture. 
Rearranged JCPyV NCCR variants from PML from patients showed EVGR promoter 
duplication and LVGR promoter deletion resulting in increased EVGR expression in 
the expense of LVGR expression similar to BKPyV.  
This study revealed an imperfect symmetry of the BKPyV EVGR and LVGR promoter 
consisting of TATA and TATA-like elements, CPEs which function in conjunction with 
Sp1 binding sites to regulate the bi-directional balance of EVGR and LVGR 
expression. This knowledge can be used to design new therapeutic approaches 
against BKPyV infection, especially in transplant patients. 
 
 
 
Manuscript under review.  
5.5 Donor-derived urothelial cancer after kidney transplantation associated 
with a BK polyomavirus with increased oncogenic potential  
 
Potentially oncoproteins, Tags are encoded by all HPyVs. These viruses can cause 
cancer by interrupting cell proliferation control. The Tags interact with tumor 
suppressors p53 and pRB and drive the cell into S-phase, when components of the 
host DNA synthesis machinery are expressed to support viral DNA replication. A key 
concept in HPyV transformation has been that of permissiveness. Once HPyV enters 
a permissive cell and EVGR, DNA replication and LVGR happen, the outcome is 
productive infection. On the other hand, when HPyV infects a cell that cannot allow 
viral genome replication and LVGR expression, but supports EVGR expression, the 
outcome is cellular transformation (17).  
BKPyV has been reported in 3 single cases of urothelial and renal tubular 
malignancies in the context of kidney transplantation. Additionally, in our study, 
BKPyV was found associated with urothelial cancer of the bladder (UC) in a kidney 
transplant recipient. The BKPyV genome was amplified by PCR from the extracted 
DNA of the tumor using outward primers from the Vp1 gene at the EcoR1 site and 
was sequenced. A full-length BKPyV genome (5116 bp) containing 17 bp deletion in 
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the p-block of the NCCR (P41-P57) and a shorter genomic fragment (3270 bp) 
lacking the NCCR, an N-terminal part of Vp2 and LTag was revealed. The viral 
genome was integrated into the cellular genome, and abundant BKPyV/SV40 LTag 
was detected in the tumor. 
For functional analysis, the UC BKPyV NCCR was cloned into the bi-directional 
reporter vector phRG, transfected in HEK293 cells and the EVGR and LVGR 
expression compared to that of BKPyV-DUN and BKPyV (ww)-NCCR reporter 
constructs. Recombinant viruses were made from two clones of the UC BKPyV 
NCCR variant and the replication was compared to that of BKPyVww, BKPyV-DUN 
and Sp1-4 BKPyV NCCR mutant described above in section 5.3. 
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The molecular characterization of the BKPyV full-length genome revealed an NCCR 
with 17 bp deletion located in a region rarely affected in other naturally occurring 
BKPyV variants. Like most rearranged BKPyV NCCR variants from patients, this 17 
bp deletion increases EVGR expression in expense of LVGR expression, and may 
contribute to the LTag expression detected in the UC. However, this deletion 
prevented progression of the viral replication cycle into the late phase, therefore 
obstructing progeny production. Integration of the viral genome into the host genome 
or LTag interaction with tumor suppressors can result to tumorigenesis. There was 
evidence of viral genome integration into the host’s chromosomes.  
Altogether, this study reports an oncogenic role of a rare BKPyV variant with a 
unique 17 bp deletion in the NCCR. This deletion activated EVGR expression in 
expense of LVGR expression however, a reduced viral replication probably due to 
integration in the cancer genome. Larger number of cases would be needed to 
confirm these findings. 
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6 DISCUSSION 
We showed that the HPyV-NCCRs differ in sequences, length, number of LTag-
binding sites and TFBS. These differences in the NCCRs and cellular transcription 
factors make-up are essential for the differences of the HPyV-NCCRs activity in the 
cell lines. Interestingly, some HPyVs demonstrated high EVGR or LVGR expression 
in cell lines derived from tissues where they were hypothesized to have tropism for, 
suggesting tissue tropism in the respective body compartment where those cells 
were derived from. LTag is vital for HPyV genome replication and LVGR expression 
(59, 262, 345). Thus, the effect of exogenous Tags expression on HPyVs EVGR and 
LVGR expression was characterized. SV40 Tags were able to activate both EVGR 
and LVGR expression from the NCCR of all HPyVs. Additionally, MCPyV cognate 
Tags activated EVGR expression from the MCPyV NCCRs, expression indicating the 
bidirectional reporter recapitulates an essential NCCR response described for the 
viral life replication cycle (25, 48, 340, 346). Replication and viral production of 
MCPyV and BKPyV in HEK293-4T cells expressing both MCPyV Tags and SV40 
Tags have been reported (347). Furthermore, BKPyV and JCPyV demonstrated 
productive replication in HEK293TT cells, expressing SV40 LTag (306). Taken 
together, these and our results support the hypothesis that cell lines expressing 
cognate Tags of respective HPyVs may support propagation of respective HPyVs. 
We also noticed that HPyVs’ number of LTag binding sites correlated with EVGR 
expression in HEK293T cells expressing SV40 Tags, indicating a role for LTag-
binding sites in HPyV EVGR and LVGR expression. The role of BKPyV LTag binding 
sites in EVGR and LVGR expression, which can be extrapolated to other HPyVs, 
was investigated for BKPyV as a model HPyV in Section 5.3. We showed that rr-
NCCR variants of HPyV7 (HPyV7-PITT1 and -2) and HPyV9 (HPyV9-UF1) from 
patients displayed higher EVGR expression compared to their respective archetype, 
indicating that rearrangements in the NCCR of novel HPyVs may also result in gain 
of function for EVGR expression and probably higher viral replication rate as 
demonstrated for clinical variants of BKPyV and JCPyV (26, 34). This result 
emphasizes the fact that the NCCR is the pathogenicity determinant of HPyVs. 
Interestingly, the higher EVGR expression pattern of the novel HPyV (rr)-NCCRs of 
HPyV7 and HPyV9 differs in the cell lines, indicating that the host cell’s TFs make-up 
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are also implicated in the NCCR-driven expression.  More so, a BKPyV variant from 
a urothelial cancer harboring a unique 17 bp deletion in the NCCR led to a gain of 
function for EVGR expression (section 5.4). This BKPyV variant expresses abundant 
LTag in the urothelial cancer, but surprisingly showed an impaired viral replication in 
vitro. This indicates that not all NCCR variants with elevated EVGR reporter 
expression correspond to an increase in viral replication, especially in the context of 
tumorigenesis. Other components of the viral-host cells interaction such as viral-
receptor entry or viral release may be involved. This impaired in vitro viral replication 
may also be due to viral integration into the host genome as reported not only in the 
urothelial cancer case study in section 5.5, but also for MCPyV integrated into the 
genome of Merkel cell carcinoma (348). The data are important for identifying host 
and viral factors vital for the replication of HPyVs in cell culture and comprehending 
secondary host cell tropism for HPyV beyond HPyV entry. This will go a long way in 
understanding the basic biology of these important human viruses. However, further 
studies are needed to determine the actual replication of some of the HPyV-NCCRs 
with high activity in cell lines. 
In the following part of the thesis we focused on the regulation of HPyVs using 
BKPyV as a model HPyV. A role of LTag binding motifs in EVGR and LVGR fold 
expression in cell lines constitutively expressing LTag was suspected, although a role 
of each particular LTag binding site is unknown. LTag-binding motif of SV40 have 
been greatly studied (59). The key feature of LTag in the NCCR of SV40 is its ability 
to bind the motifs GRGGC located at the ori, to regulate viral transcription and 
promote viral genome replication (59, 262, 345). All HPyVs including SV40 share a 
common genome architecture and all contain LTag binding sites in their NCCRs. 
However, there are some important features in which HPyVs differ. For instance, 
their secondary host cell tropism (NCCR activity in host cells), NCCR length, viral 
control elements for example, ori, EVGR and LVGR promoters, and location and 
number of LTag-binding sites. All HPyVs encode at least one LTag-binding motif 
located mostly at the ori. Since the roles of the SV40 LTag motifs are greatly known 
and the motifs between SV40, BKPyV and JCPyV at the ori are the same, we 
hypothesized that the role of the LTag binding motif in BKPyV is similar to those of 
SV40, which can be extrapolated to other HPyVs. The EVGR and LVGR expression 
of BKPyV ww-NCCR reporter with those of BKPyV ww-
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more LTag binding motifs was compared in HEK293 cells expressing no, small or 
large amounts of SV40 LTag. Eight different combinations of permutations were 
made in the BKPyV ww-NCCR LTag-binding motif (termed A, B, C, D, AC, ABC, 
ACD and ABCD). Our results revealed that EVGR expression of the ww-NCCR, 
increases in HEK239T cells and then decreases in HEK293TT cells. Mutating the 
LTag binding site A or combination of LTag binding site A with other LTag binding 
sites interestingly, abrogated this EVGR expression decrease in HEK293TT cells. 
This indicates that LTag may interact with LTag binding site A to exhibit this decrease. 
Mutation of other LTag binding sites together with LTag-binding site A did not affect 
this EVGR decrease in HEK293TT cells. With respect to the LVGR expression, all 
LTag-binding site mutants showed a proportional increase in LVGR expression in the 
presence of increasing amounts of LTag expression. Nonetheless, this proportionate 
LVGR expression is abrogated in mutants containing both A and D LTag-binding 
sites mutation. Intriguing, mutants containing either A or D LTag binding sites still 
exhibited the proportional LVGR expression. This result suggests that LTag-binding 
sites A and D may be involved in the LVGR-expression increase in the present of 
abundant LTag expression (HEK293TT cells) or the increase could be due to plasmid 
copy number effects (Fig. 4C). However, our preliminary reporter plasmid 
quantification by qPCR did not exactly correlate with the reporter constructs 
expression, thus indicating the expressing differences may not be due to plasmid 
copy number effects. The results obtained from investigating the LTag-binding sites 
of BKPyV can be extrapolated to other HPyV, such as JCPyV with similar LTag-
binding sites organization. In this study, we analyzed the effect of SV40 LTag on the 
BKPyV ww-NCCR mutants defective of LTag-binding motif knowing that one cannot 
exclude that BKPyV cognate LTag might give different results. Nonetheless, the 
SV40 and BKPyV LTag have great similarity (47) and the fact that BKPyV can 
replicate in HEK293TT cells constitutively expressing SV40 LTag argued against this 
possibility (306). EVGR and LVGR expression were analyzed using the bi-directional 
reporter vector omitting viral replication. Thus, further experiments are required to 
quantify the viral replication potential of the various NCCR mutants defective of LTag-
binding motif by cloning them in a BKPyV-dunlop backbone and perform viral 
replication studies in cell culture as previously described (34). 
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In conclusion, this thesis gave novel insights into the host and viral factors that may 
be vital for identifying suitable cell culture systems for HPyVs replication and 
prediction of HPyVs secondary host cell tropism. This will greatly enhance our 
understanding of the basic biology of HPyVs and development models for anti-viral 
testing. Finally, the effect of LTag-binding sites mutageneses suggests LTag-binding 
sites A and D may play a crucial role in the regulation of BKPyV`s EVGR and LVGR 
expression.  
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7 SUPPLEMENTARY MATERIAL AND METHODS 
 
Dual reporter design and Primers 
 
We designed a new-smaller bi-directional reporter pRG13 (Fig. 1A) based on the 
phRG reporter described in Gosert et al (Fig. 13), (25). The reporter lacks the SV40 
early promoter, beta globulin polyadenylation signal and Hygromycin gene 
sequences found in the phRG (Fig. 13). Furthermore, a derivative reporter vector 
(pRG13D12) which lacks only 12-nucleotide sequence of BKPyV ww agno gene 
(nucleotides number 4-15) compared to pRG13 was designed. The pRG13 and 
pRG13D12 reporters were designed as follows: a pBI-CMV2 plasmid (Fig. 14) 
containing a bidirectional CMV promoter, a green fluorescent protein reporter gene 
from the Aequorea coerulescens jellyfish (AcGFP1), Ampicillin resistance gene, 
SV40 poly-adenylation signals and Colicin E1 origin of replication was ordered 
(clontech, Germany). The plasmid was digested with NotI and ApaI restriction 
enzymes (New Englands Biolabs, England). The digestion product was visualized on 
a 1% agarose gel (Thermo Fischer Scientific, Switzerland). A 2385 bps fragment 
comprising of the ampicillin resistance gene, SV40 poly-adenylation signals and 
Colicin E1 was purified from the gel with the nucleospin extract II columns 
(Macherey-Nagel, Switzerland). Next, from the phGR reporter vector (25) a 1803 bps 
fragment comprising of the enhanced green fluorescence protein (EGFP), BKPyV 
Dunlop NCCR containing the 12-nucleotide sequence and the Discosoma striata red 
fuorescent protein 2 (DsRed2) was PCR amplified with primers (Table 3). The PCR 
product was digested with ApaI and NotI and then purified with the nucleospin extract 
II columns. DNA concentrations were estimated using a NanoDrop 1000 
spectrophotometer (Thermo Fischer Scientific, Switzerland). The 1803 bps fragment 
was ligated using T4 DNA ligase (New England Biolabs, England) to the ApaI/NotI 
digested pBI-CMV2 vector at insert/vector ratio of 3:1. Chemo-competent Escherichia 
coli DH5α cells (New England Biolabs, England) were transformed with the ligated 
product. Seven colonies were amplified in LB (Luria-Bertani) liquid medium (Thermo 
Fischer Scientific, USA) and plasmids were purified with the QIAprep Spin Miniprep 
Kit (Qiagen, Switzerland). Digestion of positive clones with ApaI and NotI (New 
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England Biolabs, England) was used to identify positive clones. For visualization, the 
digestion products were stained with ethidium bromide after gel electrophoresis on a 
1% agarose gel. Clones with the correct insert gave band sizes of 2385 and 1803 
bps. Using different forward and reverse primers (Table 4), the entire plasmid of one 
positive clone was sequenced using the 3130 Genetic Analyzer Sanger sequencer 
(Applied Biosystems, Switzerland). The newly designed reporter vector was called 
pRG13. The BKPyV Dunlop NCCR in the new designed reporter contained the 12-
nucleotides sequence. All HPyVs NCCRs cloned in the pRG13 lack the 12- 
nucleotides sequence, hence the name pRG13D12. HPyV NCCRs lacking the 12- 
nucleotide sequences were synthesized (Eurogentec S.A, Belgium). The NCCRs 
were excised from the pUC57 vector using the restriction enzymes BssHII and MluI 
(New England Biolabs, England). Excised DNA products were visualized on 1% 
agarose gel and NCCR DNAs were purified with the nucleospin extract II columns. 
Next, the pRG13 reporter vector containing Dunlop NCCR cloned via BssHII and 
MluI restriction sites was digested with BssHII and MluI, and visualized on 1% 
agarose gel. The plasmid backbone fragment (3782 bps) was purified with the 
nucleospin extract II column. The concentrations of the purified DNA fragments 
(NCCR and plasmid backbone) were estimated using a NanoDrop 1000 
spectrophotometer. The NCCR DNA fragments were ligated using T4 DNA ligase to 
the BssHII/MluI digested pRG13 vector at an insert/vector ratio of 3:1. Chemo-
competent Escherichia coli DH5α cells were then transformed with the ligated 
product. For each of the NCCR cloned, 10 colonies were PCR-screened with HPyV 
NCCR-specific reverse primers and a DsRed2 forward primer (Ds_Red-F1) (Table 5). 
Colonies carrying the right inserts gave an approximate size of 700 bps. Using the 
3130 Genetic Analyzer Sanger sequencer, two colonies with the right inserts were 
sequenced using HPyV NCCR-specific primers (Table 5). Colonies with the correct 
NCCR sequences was maximally amplified (maxi prep) in 400mL LB liquid medium. 
The plasmids were purified with the pure yield plasmid maxiprep System (Promega, 
Switzerland). The maxiprep plasmids were then re-sequenced. 
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Table 3: Primers for the PCR amplification of the 1803 bps fragment using phRG as 
template. 
Primer names Primer sequences 
Not1_DsRed_F CTGAGCGGCCGCCTACAGGAACAGGTGGTGG 
APa1_EGFP_R CTGAGGGCCCTTACTTGTACAGCTCGTCCATGC 
 
Table  4: Primers for sequencing the entire pRG13 reporter vector 
Primer names Primer sequences 
BKV_at_nccr_F AAGCCTCCACACCCTTACTAC 
BKV_at_nccr_R ACTCCTTTGGCCAGTTTCCAC 
Ds_Red_F_1 CATGGTCTTCTTCTGCATCAC 
Ds_Red_R_1 TCCAAGGTGTACGTGAAGCAC 
DsRed_F CTATGGAAAAACGCCAGCAACG 
DsRed_R CACAAGGCCCTGAAGCTGAAG G 
EGFP_F CAGCTCGCCGACCACTACCAG 
EGFP_R GAATAAGGGCGACACGGAAATG 
GFP_R1 GTGCTCAGGTAGTGGTTGTC 
GFP_F1 CTGAAGTTCATCTGCACCAC 
puc19_F_1 AGTGCCACCTGACGTCTAAG 
puc19_R_1 CTTACAGACAAGCTGTGACCGTC 
puc19_F_2 AGCTCACGCTGTAGGTATCTC 
puc19_R_2 TACCTCGCTCTGCTAATCCTG 
puc19_F_3 GTCTGACGCTCAGTGGAACG 
puc19_R_3 GTCAGGCAACTATGGATGAAC 
puc19_R_4 AGCTAGAGTAAGTAGTTCGCCAG 
puc19_F_4 CAACGATCGGAGGACCGAAG 
puc19_R_5 TGGTGAGTACTCAACCAAGTC 
puc19_F_5 GTATCCGCTCATGAGACAATAAC 
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Table 5: HPyV NCCR-specific primers for sequencing HPyV NCCR reporter 
constructs  
 
Primer names Primer sequences 
BKV_at_nccr_F AAGCCTCCACACCCTTACTAC  
BKV_at_nccr_R  ACTCCTTTGGCCAGTTTCCAC  
JCV_at_nccr_F  TACTTCTGAGTAAGCTTGGAG  
JCV_at_nccr_R  TATAACTGCCAGTGGCATGC  
KIPyV_nccr_F  GCACAGTGATTGACAGTTGTG  
KIPyV_nccr_R  CAGTCTTACCTGTGTCAAGGACAG  
WUPyV_nccr_F  GCTAAGCATGATTGACAGTGTG  
WUPyV_nccr_R  CCAAGGACGTCTCTGTTAAGC  
MCPyV_nccr_F  GAGCTACCTCACTAAGGAGTG  
MCPyV_nccr_R  TCTCCAGGAAATGAGTCAATGC  
HPyV-6_nccr_F  CTGTGCAGGCTTACGCAACTG  
HPyV-6_nccr_R  GTGGTCAACCTCAGTTATGACTG  
HPyV7_nccr_F AGGTGGAGGAGGAAATGTCTG 
HPyV7_nccr_R CTAAGTCCTTGACACAGCAC 
TSPyV_nccr_F  GAGGAAGTGCCAAGCCTCAAG  
TSPyV_nccr_R  CTTCCTGTGTTTGTGGCAGTATG  
HPyV9_nccr_F CAACAAGAGAAGGAGGCAAG 
HPyV9_nccr_R  GAAACCGCAATGCACTTGTTTG  
HPyV10_nccr_F AGACAGAGGCTTAGGCCTC 
HPyV10_nccr_R CTTACTGTACTTTGGAGTATTTCC 
STLPyV_nccr_F CTGTCTCTAAAGAGGCTGAGG 
STLPyV_nccr_R ACATAATGCTGTTGTTGGCTCG 
HPyV12_nccr_F CAGTACAGTGTACGTGCCTGG 
HPyV12_nccr_R CTTTAGTAGATCTTCTAGAAGGTTCAGG 
NJPyV-2013_nccr_F CTGCCTAGAAGACCTTGCAGC 
NJPyV-2013_nccr_R CAGTAACTTGCTTTCTCTTGTTTGG 
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Table 6: Proposed genera of HPyVs including LIPyV yet to be confirmed as a HPyV, 
adapted from (2).  
 
Human polyomaviruses GenBank accession number 
Genus Alphapolyomavirus  
MCPyV HM011556 
TSPyV GU989205  
HPyV9 HQ696595 
HPyV12 JX308829 
NJPyV KF954417  
LIPyV KY404016 
Genus Betapolyomavirus  
BKPyV V01108  
JCPyV AB038249 
KIPyV EF444549 
WUPyV EF444549  
Genus Deltapolyomavirus  
HPyV6 HM011563 
HPyV7 HM011567 
HPyV10 JX262162  
STLPyV JX463183  
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Fig. 13: Vector map of phRG. The bi-directional reporter vector phRG recapitulating 
the HPyV genome contains the NCCR cloned via the MluI/BssHII sites in the forward 
orientation (as in the viral genome), dsRed2 as a marker of EVGR expression and 
EGFP as marker of LVGR expression. It also contains Beta globulin poly-adenylation 
signal for stabilizing the dsRed2 and EGFP messages, SV40 early promoter for 
driving 
 
 
 
Fig. 14: Vector map of pBI-CMV2. The pBI-CMV2 vector contains a bi-directional 
CMV promoter, SV40 poly-adenylation signals for stabilizing messages, AcGFP 
reporter gene, Colicin E1 origin for bacteria replication and Ampicillin resistance gene 
for selection in bacteria. 
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Hygromycin gene, Hygromycin resistance gene for selection in eukaryotic cells, the 
ampicillin resistance gene for selection in bacteria and Colicin E1 origin for bacteria 
replication.  
 
Plasmid DNA Sequencing 
 
Dye-terminator sequencing method was used to sequence plasmid DNA. Plasmid 
DNA was first PCR amplified to obtain sufficient amounts of template DNA 
concentration. Forward and reverse amplification was performed separately. For the 
sequencing PCR, a master mix of 4 µL Big Dye vs. 3.1 (Applied Biosystem, 
Switzerland), 2 µL 5x buffer (applied Biosystem, Switzerland), 3.2 µL primer for each 
forward and reverse reaction (final concentration of 160 nM) was used. 9.2 µL of the 
master mix was pipetted into each PCR tube (Applied Biosystem, Switzerland). 
400ng template DNA was added to the mix. The final volume was adjusted to 20µL 
with H2O. Tubes were tightly closed with caps and transferred to the Veritti thermal 
cycler (Applied Biosystem, Switzerland). The PCR reaction was run with the program 
SEQAL:  
94° C    5 min 
96° C    30 sec 
55° C    15 sec 
60° C    4 min 
cooling at 10°C 
After the PCR reaction, the PCR product was purified with the NucleoSEQ columns 
(Macherey-Nagel, Switzerland) according to the manufacturer’s protocol. In brief, the 
PCR sample was applied carefully in the center of the column and spin at 750x g in 
an Eppendorf tube to recover the purified samples. The purified sample was put in a 
96-well plate (applied Biosystems, Switzerland), closed tightly with septum and put 
into the sequencing machine. The sequencing results were analyzed with SeqMan 
Pro software, version 14.0.0. 
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9 GLOSSARY 
Antibody: A protein secreted by mainly plasma cells for the neutralization of foreign 
agents, such as bacteria and virus. 
 
Acute infection: A relatively rapid disease onset, brief symptoms and disease 
cleared within days. 
 
Antigen: Any foreign molecule that can induce an immune response, especially 
producing antibodies. 
 
B recognition element: Is a cis-regulatory element immediately located upstream of 
TATA-box. 
 
Cancer: Abnormal cell growth with the ability to spread or invade other compartment 
of the body. 
 
Capsid: A protein shell for protecting a virus, consisting of small units called 
capsomeres 
 
Core promoter: It is portion of the proximal sequence upstream of a gene harboring 
the transcriptional start sites (TSS). It also contains the following; regulatory factors, 
RNA polymerase binding motif and approximately –34 base pair upstream from the 
TSS. 
 
Core promoter elements: These are sequence motifs such as initiation elements, 
TATA-box, downstream promoter elements (DPEs) and B recognition element (BRE) 
within the core promoter of a gene vital for gene transcription. 
 
Disease: a disorder that affects part or the whole body of an organism associated 
with signs and symptoms. 
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Deoxyribonucleic acid: Is a macromolecule that contains the genetic information 
vital in the development, growth, reproduction and functioning of all living organisms 
including viruses.  
 
Downstream promoter element: Is one of the core promoter elements vital for gene 
transcription by polymerase II, located downstream of the initiation element. 
 
Developmental or regulated promoter: Is a promoter with a focused TSS, TATA-
box or downstream promoter element and activated by a stimulus. 
 
Dyad symmetry: These are two regions of a DNA sequence with inverted repeats of 
each other. 
 
Encapsidation: It is a process of enclosing a viral genome in a capsid. 
 
ERAD pathway: This is a cellular pathway targeting misfolded protein from 
endoplasmic reticulum for proteasomal degradation prior ubiquitination.  
 
Housekeeping or tissue-restricted promoter: Is promoter with dispersed TSS, 
enriched with upstream BRE, contain CpG-island and constitutively active. 
 
Infection: This is the invasion of the tissues of an organism by a disease-causing 
agent. 
 
Initiation element: It is a core promoter element located downstream of a TATA box 
and upstream of a DPE, which initiate transcript even without a functioning TATA-
box. 
 
Natural killer (NK) cells: These are immune cells of the innate immune system 
exhibiting various activating and inhibitory surface receptors controlling their ability of 
kill target cells, activation and produce cytokines. 
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Nuclear localization signals: These are short amino acid sequences required for 
nuclear translocation of a protein.  
 
Open reading frame: It is a continuous region of a codon with start and stop codons 
that can encode potential proteins. 
 
Palindrome sequence: A sequence on DNA/RNA where a 5´to 3´forward sequence 
matches a sequence 5´to´3 reverse on a double helix. 
 
Pathogen: A biological agent that can cause disease. 
 
Persistent infection: This is a life-long infection which occur when a primary 
infection cannot be cleared completely by the host immune system.  
 
Promoter: DNA regions that control regulation and the initiation of transcription.  
 
Protein: A biomolecule consisting of a chain or chains of amino acids. 
 
Ribonucleic acid: It is a biomolecule with long chains of nucleotides for protein 
synthesis and containing genetic information like DNA. 
 
Recombination: A process of recombining genetic material by genetic engineering. 
 
Seroprevalence: Is the number of individuals in a population who are positive for a 
particular disease based on antibody presence in the blood against that specific 
disease.  
 
TATA-box: It is an AT-rich sequence located in the promoter of genes upstream of 
the TSS. 
 
Transcription start site: It is the region of the 3’ end of a gene where transcription 
starts. 
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Transcription factors: These are proteins that regulate the rate of transcription of 
DNA to mRNA, by specifically binding to a recognition DNA sequence. 
 
Viral reactivation: Active viral replication after a period of viral dormancy. 
 
Viremia: Presence of viral DNA in the blood. 
 
Viruria: Presence of viral DNA in the urine. 
 
Virus: A small-infectious agent that can only replicate inside a living cell. 
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